“Probably the best national conference in the world”

Early bird registration deadline: Friday 1 February 2013
Your INVITATION . . .

We do hope that you are planning to join us at Rheumatology 2013 in Birmingham. The conference is the UK’s leading rheumatology event and offers an invaluable chance for colleagues to come together to learn, network and hear about the latest developments in the field.

We are all working in an increasingly challenging environment and so it is more important than ever that we come together as a community to support each other and raise the profile of specialty.

We hope to see you in Birmingham,

Dr Chris Deighton and Mr Robert Field

What people thought about Rheumatology 2012

95% of delegates would recommend the conference to a colleague

91% say the conference is a key date in their professional calendar

95% of delegates learnt something new

75% of doctors/allied health professionals would change their practice following the conference
Key INFORMATION . . .

Rheumatology 2013 is focused on best practice in rheumatology. Sessions are designed with clear aims and outcomes, leading to effective and valuable learning opportunities for the whole rheumatology team.

WHY attend?
- A must for continuing professional development
- Innovative, engaging and interactive sessions
- Emphasis on pioneering developments
- Streamed sessions dedicated to revalidation, trainees, allied health professionals and scientists
- Peer reviewed oral and poster abstracts
- Superb networking opportunities
- Prestigious keynote lectures
- Renowned national and international speakers
- Updates on commissioning and NHS changes
- Comprehensive exhibition

WHO should attend?
Our varied conference programme appeals to all healthcare professionals with an interest in rheumatology:
- Consultant rheumatologists
- Researchers
- Doctors in training
- Scientists
- Nurse specialists
- Students
- GPs
- Occupational therapists
- Academics
- Podiatrists
- Physiotherapists
- Industry professionals

Venue
The ICC, Broad Street, Birmingham, B1 2EA

Rheumatology 2013 will be held at the ICC, in the centre of Birmingham, a vibrant city boasting excellent transport links to all parts of the UK and beyond.

Getting there
For full details of transport options, visit the ICC’s website www.theicc.co.uk/locationtravel

Accommodation
Rheumatology 2013 delegates can use the services of our accommodation agents, HG3; to take advantage of specially negotiated room rates. We have secured an allocation at a variety of hotels across the city to suit all budgets. Early booking is highly recommended, bookings made after 1 April 2013 will be subject to availability and a higher price. Bookings can be made online via www.rheumatology.org.uk/accommodation

Don’t forget to create your conference schedule
With so many high quality sessions on offer, make sure you make the most of your time at the conference with our online programme planner. View the details of the sessions on offer and build your own conference diary which you can then print off or email. Go to www.rheumatology.org.uk/programme to start planning your time at the UK’s leading rheumatology conference.

Early bird registration deadline:
Friday 1 February 2013
Tuesday 23 April, 14:00 – 16:00
Keynote: Jewels in the crown
Mr Bob Ricketts, CBE, Director of NHS Provider Transition (Department of Health), Director of Commissioning support strategy and Market Development (NHS Commissioning Board)

Bob has held a succession of senior posts at the Department of Health, all associated with reform of health services, including patient choice, commissioning (including the NHS Standard Contract), and provision (including leading the Transforming Community Services programme and development of social enterprises in health and social care). He is currently both Director of Provider Transition for the Department of Health and Director of Commissioning Support Services Strategy and Market Development for the NHS Commissioning Board, and will take up the latter post full-time from April 2013. He has featured in the Health Service Journal 100 list of the people with the greatest influence on health policy and the NHS for the last 5 years. He was awarded a CBE in last year’s New Year’s Honours list.

His interests outside work include local history and archaeology, UK postal history and Cairn Terriers.

Tuesday 23 April 16:30 – 17:30
Heberden Round
Prof Caroline Gordon, Professor of Rheumatology at the University of Birmingham and Consultant Rheumatologist at Sandwell and West Birmingham Hospitals NHS Trust and University Hospitals Birmingham NHS Foundation Trust

Caroline Gordon set up the Birmingham lupus cohort soon after her arrival in Birmingham as a clinical lecturer in 1989. She has undertaken clinical work and teaching as a consultant rheumatologist at City Hospital, Sandwell and West Birmingham Hospitals NHS Trust and the Queen Elizabeth Hospital, University Hospital Birmingham Foundation NHS Trust since 1996. She also has a clinic at Birmingham Women’s Hospital for women with systemic rheumatic diseases (particularly lupus and anti-phospholipid syndrome but including severe rheumatoid arthritis, systemic sclerosis and vasculitis) in pregnancy and for those who need pre-pregnancy counseling. The Birmingham lupus clinics have been awarded the title of LUPUS UK Centre of Excellence since 2005, the first lupus centre in the UK to receive this award. Caroline Gordon was awarded the title of Professor of Rheumatology at the University of Birmingham in 2007.

Her research programme focuses on systemic lupus erythematosus but she has contributed to research in to inflammatory arthritis, vasculitis, Sjögren’s syndrome and anti-phospholipid syndrome as well. Much of her work has focused on disease assessment for clinical trials and outcome studies, particularly the development of the BILAG disease activity index and the epidemiology of lupus. She has been involved in the development of the SLICC/ACR damage index and in the assessment of quality of life in lupus patients using the SF-36 and the Lupus QoL surveys. She has a longstanding interest in improving the treatment of systemic lupus erythematosus and has been involved in organising 3 investigator led trials. The 2 UK based trials were IV cyclophosphamide versus oral cyclophosphamide in lupus nephritis (EULAR sponsored) and cyclosporine versus azathioprine in severe SLE (Arthritis Research UK funded). She led the initiative producing EULAR points to consider for conducting clinical trials in SLE and advises the pharmaceutical industry on organising and analysing lupus clinical trials. She has been closely involved in the development of epratuzumab, an anti-CD22 targeted monoclonal antibody therapy for lupus. She has worked with Lupus UK and Lupus Europe as well as the NIHR to promote patient involvement in clinical trials. She is a consultant to the Centre for Disease Control on epidemiological studies of lupus in the USA, and to Lupus Foundation of America on their clinical trials training programme (POINT). Her other research interests include clinical and laboratory markers of disease flare, the importance of ethnicity in predicting disease susceptibility and long-term outcome, and the health of children born to mothers with lupus. She is a member of the British Isles Lupus Assessment Group (BILAG), the Systemic Lupus International Collaborating Clinics (SLICC), Co-Chair of the European League Against Rheumatism (EULAR) Task Force for Systemic Lupus Erythematosus and has been a member of several British Society for Rheumatology, American College of Rheumatology and Lupus Foundation of America committees for lupus research. She has been the lupus lead on the Arthritis Research UK systemic autoimmune disease clinical study group and Chair of the national Comprehensive Clinical Research Network (CCRN) Immunology and Inflammation Specialty Group for the National Institute for Health Research (NIHR) since 2008.
**Wednesday 24 April 16:30 – 17:30**

**Heberden Oration**

**Prof Paul Emery**, Arthritis Research UK Professor of Rheumatology, Division of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Director, Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust

Professor Emery is the Arthritis Research UK Professor of Rheumatology and Head of the Academic Division of Rheumatic & Musculoskeletal Disease, University of Leeds and the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust, U.K.

Professor Emery was President of EULAR 2009-2011, he is currently Past President. He has served on the editorial boards of all the major rheumatology journals. He was inaugural President of ISEMIR (International extremity MRI society). He is an NIHR Senior Investigator. He is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year award 1999; and EULAR prize 2002 for outstanding contribution to rheumatology research. In 2012 he was awarded the Carol Nachman Prize.

Professor Emery’s research interests centre around the immunopathogenesis and immunotherapy of rheumatoid arthritis, SpA and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation. He has published over 800 peer-reviewed articles in this area.

**Thursday 25 April, 11:30 – 13:00**

**Droitwich Lecture**

**Dr Philip Helliwell**, Senior Lecturer in Rheumatology at the University of Leeds and Honorary Consultant Rheumatologist for the Bradford Hospitals NHS Trust

Dr Helliwell is co-founder and co-lead for the Bradford (University) Diploma in Rheumatology and Musculoskeletal Medicine and is an active member of the Bradford and Airedale Musculoskeletal Alliance, a tier two service provided to GPs in the designated geographical area.

His previous and current appointments include: Member of NHS R&D Research Committee on Physical and Complex Disabilities, Member of the Executive Council, Centre for Biomechanics and Medical Engineering; Treasurer and Member of Executive Committee, Society for Back Pain Research; Member of Education Committee, Arthritis Research Campaign; and Editor for the ARC Patient Information Leaflets and Convener Publications Working Group, Member of the Heberden Committee, at the British Society for Rheumatology, Member of Council at the British Society for Rheumatology, Member of Executive Committee, Group for Research and Assessment of Psoriasis and Psoriatic arthritis.

His current and past research: treatment paradigms, clinical features and classification of psoriatic arthritis; biomechanics of joints, gait assessment and foot disorders in inflammatory and non-inflammatory arthritis, epidemiology of rheumatic disease with a longitudinal community cohort of low back pain and community based studies of psoriasis and psoriatic arthritis.

**Thursday 25 April, 14:00 – 15:30**

**Commissioning in a cold climate**

**Prof Paul Corrigan**, Former Senior Health Policy Adviser to the Prime Minister Tony Blair and Former Director of Strategy and Commissioning at the London Strategic Health Authority

Paul Corrigan gained his first degree in social policy from the LSE in 1969, his PhD at Durham in 1974. He is currently adjunct professor of public health at the Chinese University of Hong Kong and of health policy and Imperial College London.

For the first 12 years of his working life he taught at Warwick University and the Polytechnic of North London. During this period he taught, researched and wrote about inner city social policy and community development. In 1985 he left academic life and became a senior manager in London local government and in 1997 he started to work as a public services management consultant. In 1998 he published Shakespeare on Management.

From July 2001 he worked as a special adviser to Alan Milburn first and then John Reid, the then Secretary of States for Health. At the end of 2005 he became the senior health policy adviser to the Prime Minister Tony Blair. Over this six years he was instrumental in developing all the major themes of NHS reform not only in terms of policy levers but also in developing capacity throughout the NHS to use those levers.

Between June 2007 and March 2009 he was the director of strategy and commissioning at the London Strategic Health Authority.

Since then Paul has been working as a management consultant and an executive coach helping leaders within the NHS create and develop step changes within their organisation. In September 2011 he published a pamphlet “The hospital is dead Long live the Hospital” that was recognised by a leader in the Times as an important contribution to reform. As a columnist for the Health Service Journal he has continued to argue the case for NHS reform. He has an influential blog “Health Matters” that develops these issues.
### TUESDAY 23 APRIL 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 10.30</td>
<td>Faster, safer, cheaper? Advances in orthopaedic science</td>
</tr>
<tr>
<td></td>
<td>An embarrassment of riches: clinical research in rheumatoid arthritis</td>
</tr>
<tr>
<td></td>
<td>BHRP: The experience of living with musculoskeletal problems and other conditions</td>
</tr>
<tr>
<td></td>
<td>New insights on the pathogenesis and treatment of crystal arthritis</td>
</tr>
<tr>
<td></td>
<td>Oral abstracts: Connective tissue disease</td>
</tr>
<tr>
<td></td>
<td>SIG: Spondyloarthritis</td>
</tr>
<tr>
<td></td>
<td>BHRP SIG: Connective tissue disease</td>
</tr>
<tr>
<td>10.30 – 11.30</td>
<td>Poster viewing and exhibition</td>
</tr>
<tr>
<td>11.30 – 13.00</td>
<td>BHRP: Interactive panel discussion and problem solving to optimise work participation</td>
</tr>
<tr>
<td></td>
<td>BSR/BHRP: Facilitating adherence to treatment in rheumatology</td>
</tr>
<tr>
<td></td>
<td>Osteoporosis: an update</td>
</tr>
<tr>
<td></td>
<td>Biologics in connective tissue disease</td>
</tr>
<tr>
<td></td>
<td>Oral abstracts: Pathogenesis</td>
</tr>
<tr>
<td></td>
<td>SIG: Musculoskeletal pain</td>
</tr>
<tr>
<td></td>
<td>SIG: Foot and ankle</td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>Exhibition</td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>BSR/BHRP: Post graduate research student network</td>
</tr>
<tr>
<td></td>
<td>Register open meeting</td>
</tr>
<tr>
<td>14.00 – 16.00</td>
<td>Jewels in the Crown</td>
</tr>
<tr>
<td></td>
<td>Within the prestigious Jewels in the Crown plenary session, chaired by the presidents of BSR and BHRP, we will be showcasing the top scoring abstracts and awarding the Michael Mason and Garrod Prize winners.</td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td>Exhibition</td>
</tr>
<tr>
<td>16.30 – 17.30</td>
<td>Heberden Round</td>
</tr>
<tr>
<td>17.30 – 19.15</td>
<td>Industry supported symposia (including catering): Roche</td>
</tr>
<tr>
<td>19.30 – 21.30</td>
<td>Presidents’ reception</td>
</tr>
</tbody>
</table>

### WEDNESDAY 24 APRIL 2013

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00 – 08.30</td>
<td>Industry supported symposia (including catering): Actelion</td>
</tr>
<tr>
<td></td>
<td>Industry supported symposia (including catering): Pfizer</td>
</tr>
<tr>
<td>09.00 – 10.30</td>
<td>BHRP: Are our interventions cost-effective?</td>
</tr>
<tr>
<td></td>
<td>BHRP: Measuring disease activity in RA, when your patient is in remission</td>
</tr>
<tr>
<td></td>
<td>Essentials in rheumatology: Disease management</td>
</tr>
<tr>
<td></td>
<td>Managing the care gap: implementing evidence-based practice in primary care</td>
</tr>
<tr>
<td></td>
<td>Ultrasound: what is in it for you?</td>
</tr>
<tr>
<td></td>
<td>Getting to grips with the use of social media tools in rheumatology</td>
</tr>
<tr>
<td></td>
<td>Oral abstracts: Adolescent and young adult</td>
</tr>
<tr>
<td></td>
<td>SIG: Education</td>
</tr>
<tr>
<td>10.30 – 11.30</td>
<td>Poster viewing and exhibition</td>
</tr>
<tr>
<td>11.30 – 13.00</td>
<td>Musculoskeletal clinical networks in the new NHS landscape</td>
</tr>
<tr>
<td></td>
<td>Arthritis pain: mechanisms, meaning and medicines</td>
</tr>
<tr>
<td></td>
<td>Essentials in rheumatology: Symptoms diagnosis and management</td>
</tr>
<tr>
<td></td>
<td>The emerging role of epigenetics in rheumatic diseases</td>
</tr>
<tr>
<td></td>
<td>BHRP plenary oral</td>
</tr>
<tr>
<td></td>
<td>Oral abstracts: Primary care</td>
</tr>
<tr>
<td></td>
<td>SIG: MSK disorders in ethnic minorities</td>
</tr>
<tr>
<td></td>
<td>SIG: Adolescent and young adult</td>
</tr>
<tr>
<td></td>
<td>SIG: Ultrasound</td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>Exhibition</td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>BSR AGM</td>
</tr>
<tr>
<td>16.00 – 16.30</td>
<td>Exhibition</td>
</tr>
<tr>
<td>16.30 – 17.30</td>
<td>Adolescent and young adult</td>
</tr>
<tr>
<td>17.30 – 19.15</td>
<td>Industry supported symposia (including catering): Abbott</td>
</tr>
<tr>
<td>19.30 – Late</td>
<td>Conference dinner</td>
</tr>
</tbody>
</table>

---

* Correct at the time of printing, but is subject to change.*
THURSDAY 25 APRIL 2013

07.00 – 08.30
• Industry supported symposia (including catering): Bristol-Myers Squibb

09.00 – 10.30
• Ageing and the musculoskeletal system
• Ask the experts
• BSR/BHPR: Advanced practice in osteoarthritis
• Mortality in rheumatic disease
• BHPR: Introducing cognitive behavioural approaches to rheumatic disease: top tips and tools for clinic
• Oral abstracts: RA Clinical
• SIG: Heritable disorders of connective tissue
• SIG: Sjögren’s

10.30 – 11.30 Poster viewing and exhibition | Tea and coffee

11.30 – 13.00
• Droitwich
• Polymyalgia rheumatic and giant cell arthritis
• Interactive clinical teaching: osteoporosis
• Oral abstracts: Genetics
• Oral abstracts: Science
• SIG: Scleroderma
• SIG: Soft tissue rheumatism and sports medicine

13.00 – 14.30 Exhibition | Lunch

13.00 – 14.00
• BHPR AGM
• RATs AGM
• Standards, audit and guidelines working group open meeting

14.00 – 15.30
• Advances in cartilage biology: towards a better understanding of osteoarthritis
• BHPR: The use of ultrasound for nurses and allied health professionals
• Career development for new consultants
• Commissioning session
• BHPR: The importance of health literacy in musculoskeletal disease
• Oral abstracts: Spondyloarthritis
• SIG: Myositis
• SIG: Rheumatoid arthritis

16.00 – 17.30
• SIG: Genetics
• SIG: Osteoarthritis arthritis
• SIG: RA outcomes
• SIG: Vasculitis
• SIG: Interstitial lung disease

17.30 Meeting Close

Poster tours

Tuesday 23 April 2013 | 10.30 – 11.30
Poster Tours
RA clinical
RA pathogenesis
Case reports

Wednesday 24 April 2013 | 10.30 – 11.30
Poster Tours
BHPR
SLE and antiphospholipid syndrome
Education

Thursday 25 April 2013 | 10.30 – 11.30
Poster Tours
Epidemiology
Connective tissue disease
Spondyloarthropathy

“A first-rate conference that is a must for all who treat patients with rheumatological conditions”

“I found it very stimulating and I learned things that will change my practice”
### New insights on the pathogenesis and treatment of crystal arthritis

**Chairs:** Dr Edward Roddy, Arthritis Research UK, Keele University, Keele and Prof George Nuki, University of Edinburgh, Edinburgh

**Aim:**
Provide an update on the causes and optimal treatments of common crystal arthropathies

**Outcome 1:**
Understand the genetic and environmental risk factors for crystal arthritis

**Outcome 2:**
Understand the potential importance of treating to target for gout

**Outcome 3:**
Update on existing and new therapeutic options

- **09.00**  
  Gout: should we treat to target?  
  Prof Pascal Richette, Universite Paris 7, Paris, France

- **09.30**  
  Pathogenesis and treatment of pyrophosphate arthropathy  
  Prof Geraldine McCarthy, Mater Misericordiae University Hospital, Dublin, Ireland

- **10.00**  
  Genetic and environmental risk for hyperuricaemia and gout  
  Prof Michael Doherty, University of Nottingham, Nottingham

### Faster, safer, cheaper? Advances in orthopaedic science

**Chairs:** Dr Fraser Birrell, University of Newcastle, Newcastle and Prof George Peat, Keele University, Keele

**Aim:**
Joint surgery is undergoing a scientific revolution, with dogma being replaced by evidence based practice. The aim of the this session is to highlight some key advances:

**Outcome 1:**
Delegates will know about the introduction of fast track surgery (which has reduced complication rates)

**Outcome 2:**
Delegates will understand the National Joint registry (which has guided use of particular implants), and the shift in focus towards Patient Reported Outcome Measure (PROMS)

**Outcome 3:**
Delegates will recognise the problems with resurfacing procedures

- **09.00**  
  Fast-track hip and knee arthroplasty: current status and future challenges  
  Mr Henrik Husted, Hvidovre University Hospital, Hvidovre, Denmark

- **09.25**  
  Lessons from the national joint registry and patient reported outcome measures (PROMS)  
  Mr Simon Jameson, National Joint Registry, Middlesbrough

- **09.50**  
  Insights into hip resurfacing and what happened with metal on metal implants  
  Mr Mike Reed, Northumbria Healthcare NHS Foundation Trust, Ashington

- **10.15**  
  Panel Discussion

### An embarrassment of riches: clinical research in rheumatoid arthritis

**Chair:** Prof John Isaacs, University of Newcastle, Newcastle

**Aim:**
To highlight the patient benefits of research involvement, and to raise the notion that recruitment of patients into research should be considered a ‘quality measure’

**Outcome 1:**
To demonstrate patient benefits of involvement in clinical research

**Outcome 2:**
To highlight, contrast and raise awareness of the wide variety of research opportunities for RA patients

**Outcome 3:**
To stimulate debate around distinct research opportunities – is a phase III pharmaceutical industry trial better for my patients than a phase I experimental medicine study? Should economic considerations influence my decision? Should trial recruitment become an auditable quality measure for rheumatologists?

- **09.00**  
  How clinical research improves patient outcomes  
  Dr A Murray Brunt, University Hospital of North Staffordshire, Stoke-on-Trent

- **09.15**  
  How research changed my life  
  Mrs Ailsa Bosworth, NRAS - National Rheumatoid Arthritis Society, Berkshire

- **09.30**  
  Should it be standard of care to offer entry to research trials at each therapeutic decision stage of the patient journey?  
  Dr Maya Buch, University of Leeds, Leeds

- **09.45**  
  Research opportunities for the RA patient, their rheumatologist, and their AHP, including economic aspects  
  Prof Deborah Symmons, University of Manchester, Manchester

- **10.00**  
  Recruitment of RA patients into research should provide an auditable quality measure  
  Dr Peter Dawes, Haywood Hospital, Stoke-on-Trent and Dr Ian Rowe, Worcestershire Royal Hospital, Worcester
**BHPR: The experience of living with musculoskeletal problems and other conditions**

*Chairs: Prof Bie Nio Ong, Keele University, Keele and Mrs Jenny Ratcliffe, East Cheshire NHS Trust, Macclesfield*

**Outcome 1:** To appreciate the complex nature of multimorbidity, in particular, that it can consist of many different combinations of conditions and thus result in a wide range of impacts on individuals’ quality of life and their use of health care.

**Outcome 2:** Through discussion begin to formulate how health professionals can best respond to the complexity of multimorbidity.

09.00 Multimorbidity, quality of care and self-management in patients with arthritis and long-term conditions: analyses from a prospective primary care cohort

*Prof Peter Bower, University of Manchester, Manchester*

09.15 The role of patients’ social networks in shaping the experience of musculoskeletal conditions and multimorbidity

*Mr Tom Porter, Keele University, Stoke-On-Trent, Keele*

09.30 Do people with chronic musculoskeletal problems and multimorbidity set priorities?

*Dr Sudeh Cheraghi-Sohi, Keele University, Keele*

**Oral abstracts: Connective tissue disease**

09.00 Long-term outcomes of children born to mothers with SLE

*Dr Mary Gayed, Sandwell and West Birmingham Hospitals, Birmingham*

09.15 Higher corticosteroid doses early in disease have a long-term influence on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

*Dr Benjamin Parker, University of Manchester, Manchester*

09.30 Simple insoles for managing foot problems in people with SSC: the Pisces randomized controlled trial

*Dr Anthony Redmond, University of Leeds, Leeds*

09.45 A retrospective study of long-term outcome in 152 patients with primary Sjögren’s syndrome – 25 year experience

*Ms Esha Abrol, University College London Medical School, London*

10.00 Successful use of Tocilizumab in the treatment of refractory FDG pet positive large vessel vasculitis: a case series

*Dr Sanam Kia, Southend Hospital, Southend-on-Sea*

10.15 Factors associated with long-term damage in the ANCA-associated vasculitides: an analysis of cohorts from the European vasculitis study group (EUVAS) therapeutic trials

*Dr Joanna Robson, University of Oxford, Oxford*
09.00 – 10.30 SIG: Spondyloarthritis
Chairs: Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath and Prof Dennis McGonagle, University of Leeds, Leeds

Aim:
To increase awareness of advances in diagnosis, management, biomarkers and clinical trials in the field of spondyloarthritis

Outcome 1:
Attendees will understand the treatment of axial spondyloarthritis

Outcome 2:
Attendees will be updated on the current clinical trials in spondyloarthritis

Outcome 3:
Attendees will be updated on the role of biomarkers in diagnosing and assessing spondyloarthritides

09.00  Welcome and introduction
Prof Dennis McGonagle, University of Leeds, Leeds and Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.10  Treating non radiographic axial spondyloarthritis?
Dr Lesley Kay, University of Newcastle, Newcastle

09.30  Current clinical trials in AS
Dr Jon Packham, University Hospital of North Staffordshire, Staffordshire

09.50  Update on new biologics in PsA
Prof Dennis McGonagle, University of Leeds, Leeds

10.10  What is the best way to do clinical screening for PsA in dermatology setting
Dr Philip Helliwell, University of Leeds, Leeds

09.00 – 10.30 BHPR SIG: Connective tissue disease
Chair: Ms Sue Brown, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

Aim:
To address musculoskeletal health in pregnancy and explore the role of the multi-disciplinary team

Outcome 1:
To give an overview of the important aspects of managing women in pregnancy and when to act on red flags

Outcome 2:
To consider the important role of physiotherapists and nurses in managing pregnancy in rheumatology

Outcome 3:
To provide information about medications that are safe to use in pregnancy and discuss some of the potential problems that may arise due to medication

09.00  Setting up a rheumatology pregnancy clinic
Dr Maddy Piper, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.20  Pre-pregnancy counselling: the role of the nurse
Ms Sue Brown, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

09.30  Physiotherapy interventions in managing musculoskeletal pain in pregnancy
Dr Yvonne Coldron, Croydon University Hospital, Croydon

10.10  Medications in pregnancy
Dr Mary Gayed, University of Birmingham, Birmingham

10.30 – 11.30 Poster viewing and exhibition | Tea and Coffee

Categories
Case reports
Imaging
Metabolic and crystal arthropathies
Rheumatoid arthritis: pathogenesis and animal models
Rheumatoid arthritis: treatment
Rheumatoid arthritis: clinical features
Rheumatoid arthritis: comorbidities

Poster Tours
RA clinical
RA pathogenesis
Case reports
### NEW – Innovation theatre: Roche
ANCA - associated vasculitis for rheumatologists  
**Speaker:** Professor David Scott, Norfolk and Norwich University Hospital, Norwich

### BSR/BHPR: Facilitating adherence to treatment in rheumatology
**Chairs:** Prof Anne Barton, University of Manchester, Manchester and Dr Claire Goodchild, King’s College London, London

**Aim:** To provide clinicians with an overview of the patient factors that could affect adherence to treatment and how this information could be used to facilitate adherence

- **Outcome 1:** Attendees will understand some of the health beliefs which may impact on non-adherence to treatment
- **Outcome 2:** Attendees will understand some of the behaviour change strategies which may be employed in clinical practice to facilitate adherence to pharmacological and physical therapies

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.30 | Patient non-adherence to treatment: what causes it and what can be done about it  
Prof John Weinman, Institute of Psychiatry, London |
| 12.00 | Adherence and adaptation: targeting beliefs and behaviour in optimising self management  
Dr Lis Cordingley, University of Manchester, Manchester |
| 12.30 | The clinical application of behaviour change strategies to facilitate adherence to treatment  
Dr Sarah Dean, University of Exeter, Exeter |

### Osteoporosis: an update
**Chair:** Dr Emma Clark, University of Bristol, Bristol

**Aim:** To provide general rheumatologists and trainees with an update on metabolic bone disease

- **Outcome 1:** To understand investigation and management of renal bone disease
- **Outcome 2:** To highlight the emerging idea of sarcopaenia and its importance to bone  
To discuss the role of drug holidays for bisphosphonates
- **Outcome 3:** To discuss the role of drug holidays for bisphosphonates

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.30 | An update on investigation and management of renal bone disease  
Prof David Hoskin, City Hospital, Nottingham |
| 12.00 | Sarcopaenia: is it a disease and can it be treated?  
Prof Avan Aihie Sayer, University of Southampton, Southampton |
| 12.30 | Long-term treatment with bisphosphonates: what to do after five years?  
Prof Juliet Compston, University of Cambridge, Cambridge |

### Biologics in connective tissue disease
**Chairs:** Dr Hector Chinoy, University of Manchester, Manchester and Dr Benjamin Parker, University of Manchester, Manchester

**Outcome 1:** To discuss recent clinical trials of rituximab in ANCA-associated vasculitis

**Outcome 2:** To review the use of available biologics in SLE and introduce emerging therapies

**Outcome 3:** To review the use of novel biologic agents in severe haematological manifestations of CTD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11.30 | Rituximab in ANCA-associated vasculitis  
Dr Chetan Mukhtyar, Norfolk and Norwich University Hospital, Norwich |
| 12.00 | Current and emerging biologics in SLE  
Prof Ian Bruce, University of Manchester, Manchester |
| 12.30 | Novel biologics in severe haematological manifestations of connective tissue disorders  
Dr Jecko Thachil, Manchester Royal Infirmary, Manchester |
**BHPR: Interactive panel discussion and problem solving to optimise work participation**

**Chairs:** Dr Victoria Chamberlain, Trafford Healthcare NHS Trust, Manchester and Mr Federico Moscogiuri, ARMA, London

**Aim:** To provide delegates with the opportunity to discuss ways to optimise work participation

**Outcome 1:** To review the determinants of reduced work participation for adults with musculoskeletal conditions

**Outcome 2:** To outline ways to reduce the barriers and improve work participation

**Outcome 3:** To identify issues which need further review by clinicians and policy makers e.g. Department for Work and Pensions to improve work participation

**11.30**  
Work and musculoskeletal conditions: the key issues  
Dr Ross Wilkie, Keele University, Keele

**11.45**  
Interactive panel discussion and problem solving to optimise work participation  
Prof Dame Carol Black, Health and Work, London, Dr Bill Gunnyeon, Department for Work and Pensions, London, Dr David Walker, Freeman Hospital, Newcastle and Ms Adele Higginbottom, Keele University, Keele

---

**Oral abstracts: Pathogenesis**

**11.30**  
Characterising type 17 immune responses in ankylosing spondylitis  
Dr Mohammad Hussein Al-Mossawi, Oxford University, Oxford

**11.45**  
Synovial lymphocyte aggregates in early inflammatory arthritis: correlation with diagnosis, disease activity and antibody status  
Dr Maria Di Cicco, Queen Mary University of London, London

**12.00**  
Early treatment-naive rheumatoid arthritis (RA) is characterised by qualitative changes of the INKT regulatory cell repertoire  
Prof Stephan Gadola, University of Southampton and UHS NHS Foundation Trust, Southampton

**12.15**  
Widespread citrullination in healthy and inflamed lung tissue as a priming site for autoimmunity in RA  
Dr Elena Lugli, Kennedy Institute of Rheumatology, London

**12.30**  
How does PTPN22 regulate T cell effector responses in inflammatory arthritis?  
Dr Cristina Sanchez-Blanco, King’s College London, London

**12.45**  
Clinical significance of IL-6 and CCL2 upregulation in serum and renal biopsies from cases of sclerodema renal crisis  
Dr Cassandra Hong, King’s College Hospital, London

---

**SIG: Musculoskeletal pain**

**Chair:** Dr Nicholas Shenker, Cambridge University Hospitals, Cambridgeshire

**Aim:** Engagement for members to understand and develop commissioning for musculoskeletal pain services; opportunity for clinical research studies to be discussed, from inception through to delivery; plan for the future of the MSK pain SIG

**Outcome 1:** To be able to understand what projects are currently being developed and what clinical trials have come to fruition from the Arthritis Research UK pain study group. To understand the process of how to engage with this and take forward ideas

**Outcome 2:** To be able to understand the commissioning environment. To be able to come up to date with the national pathways that have been developed as part of the British Pain Society’s endeavours working with the Department of Health

**Outcome 3:** To engage with the SIG members of what they would want a SIG to include, whether that be audits, surveys, support or newsletters. To request for volunteers who wish to be included in this to commit time and resources as necessary

**11.30**  
Arthritis Research UK’s Musculoskeletal pain study group: current trials and how to get involved  
Prof Elaine Hay, Keele University, Keele

**12.00**  
The commissioning climate for musculoskeletal pain services  
Dr Benjamin Ellis, King’s College Hospital, London

**12.30**  
Musculoskeletal Pain SIG: what do we want from it?  
Dr Nicholas Shenker, Cambridge University Hospitals, Cambridge
**11.30 – 13.00**

**SIG: Foot and ankle**

*Chair: Dr Anthony Redmond, University of Leeds, Leeds*

**Aim:**

The session will focus on gout, the arthritis most typically characterised by foot involvement. Delegates will be updated about how and why gout affects the foot and the emerging role of ultrasound for assessing joint involvement in gout.

**Outcome 1:**

Delegates will gain knowledge of how the foot is affected by gout, both in the acute attack and chronically.

**Outcome 2:**

Delegates will understand the pathophysiological mechanisms underlying the predilection of gout for the joints of the foot.

**Outcome 3:**

Delegates will appreciate the potential role of ultrasound in the diagnosis and assessment of gout.

11.30

**Gout and the foot: a clinical overview**

*Dr Kristin Kay Willits Jordan, Brighton and Sussex University Hospitals, Brighton*

11.50

**The role of footwear in gout**

*Prof Keith Rome, Auckland University of Technology, Auckland, New Zealand*

12.10

**Why does gout target the foot: a critical role for osteoarthritis?**

*Dr Edward Roddy, Arthritis Research UK Primary Care Centre, Keele*

12.30

**Ultrasound assessment of the foot in gout**

*Prof Pascal Richette, Universite Paris 7, Paris, France*

**13.00 – 14.00**

Exhibition | Lunch

**13.00 – 13.30**

NEW – Innovation theatre: **Abbott**

State of the art ultrasound imaging: in your clinical practice

*Speaker: Dr Cristina Estrach, Aintree University Hospitals NHS Foundation Trust, Liverpool*

**13.30 – 14.00**

NEW – Innovation theatre: **Savient**

*Speaker: To be announced*

**13.00 – 14.00**

**Registers open meeting**

**Aim:**

To inform all those wanting to understand the implications of Register Research for their practice.

- Update members on the latest results and analysis from the RA and AS registers.
- Update the membership on how to recruit and how to access data from the registries for audit and research.
- Provide insight into how the registers will develop in the coming years with the advent of electronic data entry.

**Outcome 1:**

Open to all with an interest in the Biologics Registers, whether as a contributor of patient data or as a researcher interested in accessing the data. There will be an update of the latest news on recruitment and research.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00</td>
<td><strong>BSR/BHPR: Post graduate research student network</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dr Annette Bishop, Arthritis Research UK, Keele University,</td>
</tr>
<tr>
<td></td>
<td>Keele and Prof Sarah Hewlett, University of the West of England, Bristol</td>
</tr>
<tr>
<td></td>
<td><strong>Aim:</strong> To provide a coordinated network for early career researchers</td>
</tr>
<tr>
<td></td>
<td>that facilitates peer group discussion and support from a range of</td>
</tr>
<tr>
<td></td>
<td>leading academics</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 1:</strong> Attendees will participate in a structured networking</td>
</tr>
<tr>
<td></td>
<td>event with different seniority levels of researchers to find</td>
</tr>
<tr>
<td></td>
<td>common interests and build future collaborations</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 2:</strong> Attendees will practice effectively communicating their</td>
</tr>
<tr>
<td></td>
<td>current research study</td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 3:</strong> Attendees will contribute to a networking database that</td>
</tr>
<tr>
<td></td>
<td>will be circulated after the event to enable contacts to become</td>
</tr>
<tr>
<td></td>
<td>established</td>
</tr>
<tr>
<td>13.00</td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>13.05</td>
<td><strong>Planning your elevator pitch</strong></td>
</tr>
<tr>
<td>13.10</td>
<td>**Structured “speed dating” educational networking facilitated by</td>
</tr>
<tr>
<td></td>
<td>academics**</td>
</tr>
<tr>
<td>14.00</td>
<td><strong>Jewels in the crown</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs:</strong> Dr Chris Deighton, President BSR and Mr Robert Field,</td>
</tr>
<tr>
<td></td>
<td>President BHPR</td>
</tr>
<tr>
<td></td>
<td><strong>Introduction</strong></td>
</tr>
<tr>
<td>14.00</td>
<td><strong>The new commissioning landscape: opportunities and challenges</strong></td>
</tr>
<tr>
<td>14.05</td>
<td>**Mr Bob Ricketts, Director of NHS Provider Transition (Department of</td>
</tr>
<tr>
<td></td>
<td>Health) and Director of Commissioning Support Strategy and Market</td>
</tr>
<tr>
<td></td>
<td>Development (NHS Commissioning Board), London</td>
</tr>
<tr>
<td>14.40</td>
<td><strong>Michael Mason prize winner:</strong> Dr Nidhi Sofat, St George’s University</td>
</tr>
<tr>
<td>14.55</td>
<td><strong>Garrod prize winner:</strong> Dr Charis Pericleous, University College</td>
</tr>
<tr>
<td>15.10</td>
<td>**Randomised controlled trial of tumour-necrosis-factor inhibitors</td>
</tr>
<tr>
<td></td>
<td>(TNFi’s) against combination intensive therapy with conventional</td>
</tr>
<tr>
<td></td>
<td>disease modifying anti-rheumatic drugs (cDMARDs) in established</td>
</tr>
<tr>
<td></td>
<td>rheumatoid arthritis (RA): the TACTIT trial</td>
</tr>
<tr>
<td>15.25</td>
<td><strong>Epigenetic regulation of the IL23R locus in ankylosing spondylitis</strong></td>
</tr>
<tr>
<td>15.40</td>
<td>**SARAH: strengthening and stretching for people with rheumatoid</td>
</tr>
<tr>
<td></td>
<td>arthritis of the hands: a randomised controlled trial</td>
</tr>
<tr>
<td>16.00</td>
<td>**Exhibition</td>
</tr>
<tr>
<td>16.30</td>
<td><strong>Heberden Round</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Prof Caroline Gordon, University of Birmingham, Birmingham</strong></td>
</tr>
</tbody>
</table>
17.30 – 21.00

Tuesday 23 April 2013 | INDUSTRY SUPPORTED SYMPOSIUM | NETWORKING

17.30 – 17.45

Industry supported symposia catering

17.45 – 19.30

Industry supported symposia: Roche
Challenging Expectations in RA Outcomes: Disease remission is achievable for patients on therapy without Methotrexate
Chair: Prof Ernest Choy, University of Cardiff, Cardiff

Welcome and introduction
Presenting the case: patients who cannot take MTX
Prof Ernest Choy, University of Cardiff, Cardiff
Assessing the evidence: patients who cannot take MTX
Speaker to be announced
Assessing the evidence: remission versus response
Speaker to be announced
Assessing the evidence: safety of biologic therapy without MTX
Speaker to be announced
Question and Answer session
Panel
Summary and Close
Prof Ernest Choy, University of Cardiff, Cardiff

19.30 – 21.30

President’s reception

The presidents of BSR and BHPR invite you to join them at this dedicated networking event at the nearby Birmingham Town Hall, which will provide the perfect opportunity to meet and continue your discussions with rheumatology colleagues and industry peers in a relaxed and informal setting.

Drinks and canapés will be provided | This event is free to attend for registered delegates
### Industry supported symposia: Actelion

**Digital Ulcers (DU) as a complication of Systemic Scleroderma (SSc): Management and prevention strategies**

*Chair: Prof Chris Denton, University College Medical School, London*

**Aim:**
To provide delegates with up-to-date information on management strategies for DU patients and to discuss the importance of measuring outcomes in treatment success.

**Format:** Six-physician panel to discuss the optimal management and latest recommendations in the treatment of DU patients. This is an interactive session for delegates with the use of voting keypads.

**Outcome 1:** Delegates will be able to understand DU as a complication of SSc.

**Outcome 2:** Delegates will be able to understand optimal multidisciplinary management strategies in SSc and the importance of measuring outcomes.

**Outcome 3:** Delegates will be able to understand the importance of a preventative approach to DU management.

Panel to be confirmed.

### Industry supported symposia: Pfizer

**Essentials in rheumatology: Disease management**

*Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College, London*

**Aim:**
A comprehensive update covering everything you need to know about changes in rheumatology.

To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees.

Delegates will have been brought up to date on disease management.

#### Outcome 1:
**Recognition and management of the auto-inflammatory diseases**

*Prof Dennis McGonagle, University of Leeds, Leeds*

*Dr Frank McKenna, Central Manchester University Hospitals NHS Foundation Trust, Manchester*

*Dr Toby Maher, Imperial College London, London*
### Getting to grips with the use of social media tools in rheumatology

**Chair:** Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath

**Aim:** To provide an overview of the potential use of new media to enhance communication in our practice of rheumatology

**Outcome 1:** Delegates will be aware of the potential of social media to help clinicians improve communication with patients and colleagues including GPs and allied health professionals

**Outcome 2:** Delegates will be aware of eLearning tools used to enhance education and know how they can contribute to the creation of educational material in new formats

**Outcome 3:** Delegates will be aware of how to plan and manage their online ‘presence’, mindful of professional issues

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>How to learn using social media technologies</td>
<td>Dr Ronan Kavanagh, Bon Secours Hospital, Galway, Ireland</td>
</tr>
<tr>
<td>09.30</td>
<td>Social media and academia</td>
<td>Dr Anne-Marie Cunningham, University of Cardiff, Cardiff</td>
</tr>
<tr>
<td>10.00</td>
<td>Connecting with charities and patients using social media</td>
<td>Dr Martin Lee, Freeman Hospital, Newcastle</td>
</tr>
</tbody>
</table>

### Ultrasound: what is in it for you?

**Chairs:** Dr Zunaid Karim, Midyorkshire NHS Trust, Pontefract and Prof Peter Taylor, University of Oxford, Oxford

**Aim:** To provide rheumatologists with an outline of how using ultrasound can improve the care they offer to patients for each of the lecture

**Outcome 1:** Delegates will be aware of the role ultrasound has played in improving the understanding and management of conditions discussed

**Outcome 2:** Delegates will be able to recognise clinical situations where ultrasound is likely to benefit care Delegates will have a better understanding of current and future ultrasound research with potential future role

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Ultrasound in rheumatoid arthritis</td>
<td>Dr Richard Wakefield, Chapel Allerton Hospital, Leeds</td>
</tr>
<tr>
<td>09.30</td>
<td>Ultrasound in spondyloarthopathy</td>
<td>Prof David Kane, Adelaide and Meath Hospital, Dublin, Ireland</td>
</tr>
<tr>
<td>10.00</td>
<td>Ultrasound in vasculitis</td>
<td>Prof Wolfgang Schmidt, Medical Centre for Rheumatology, Berlin, Germany</td>
</tr>
</tbody>
</table>

### BHPR: Are our interventions cost-effective?

**Chairs:** Dr Martyn Lewis, Arthritis Research UK, Keele University, Keele and Dr Lindsay Beame, King’s College London, London

**Aim:** To provide an overview of health economics and cost-evaluation of interventions provided by health professionals in rheumatology

**Outcome 1:** Delegates will be aware of basic concepts of health economics in the context of health and healthcare and how this influences policy

**Outcome 2:** Delegates will have an increased awareness of the need for cost-evaluation of their interventions and the main types of cost-evaluation in healthcare

**Outcome 3:** Delegates will have a better understanding of current and future ultrasound research with potential future role

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Considerations for health economics analysis in rheumatology</td>
<td>Dr Tracey Young, University of Sheffield, Sheffield</td>
</tr>
<tr>
<td>09.30</td>
<td>The cost-effectiveness of nurse-led care in people with RA</td>
<td>Dr Mwidimi Ndosi, University of Leeds, Leeds</td>
</tr>
<tr>
<td>09.55</td>
<td>Cheap as chips and less fattening: Economic evaluation of ‘ESCAPE-pain’ an integrated rehabilitation programme for chronic knee pain/OA</td>
<td>Prof Michael Hurley, St Georges University of London and Kingston University, London</td>
</tr>
</tbody>
</table>
Managing the care gap: implementing evidence-based practice in primary care
Chair: Dr Philip Helliwell, University of Leeds, Leeds

Aim: To highlight gaps between musculoskeletal research evidence and current primary care practice, updating delegates about the evidence and how the gaps can be addressed

Outcome 1: Increased knowledge of what current best practice for osteoarthritis, back pain and osteoporosis in primary care should be

Outcome 2: Understanding of how current clinical practice in primary care differs from the research evidence

Outcome 3: Awareness of how rheumatologists and general practitioners can work together to address these gaps in care

09.00 – 10.30 Oral abstracts: Adolescent and young adults

09.00 Hypermobility is a risk factor for musculoskeletal pain in adolescence: findings from a prospective cohort study
Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath

09.15 The association between gastrointestinal symptoms and the joint hypermobility syndrome in a population of university students
Dr Asma Fikree, Blizard Institute of Cell and Molecular Science, London

09.30 A comparison of the outcome of adolescent and adult onset systemic lupus erythematosus
Dr Grainne Murphy, University College London, London

09.45 Anti-NXP2 autoantibody status is a predictor of calcinosis in older but not younger children who develop juvenile dermatomyositis
Dr Sarah Tansley, Royal National Hospital for Rheumatic Diseases, Bath

10.00 Catch-up growth during Tocilizumab therapy for systemic juvenile idiopathic arthritis (SJIA): tender 2-year data
Speaker to be announced

10.15 Efficacy and safety of Tocilizumab in polyarticular juvenile idiopathic arthritis (PCJIA): cherish results at week 40
Dr Athimalaipet Ramanan, Bristol Royal Hospital for Children and Royal National Hospital for Rheumatic Diseases, Bath

09.00 – 10.30 SIG: Education
Chair: Prof Andrew Hassell, Haywood Hospital, Stoke-on-Trent and Keele University School of Medicine, Keele

Aim: To promote the development of rheumatology education to patients and health professionals within rheumatology, to develop networks of rheumatology education, to develop collaborative research and development projects within rheumatology

Outcome 1: For interested participants to progress a national project around the use and development of REMs in undergraduate medical education and to explore its potential in the education of rheumatology nurses and allied health professionals

Outcome 2: To provide a forum for sharing and developing ideas in the field of education in rheumatology

Outcome 3: For participants to receive an update on the work of Arthritis Research UK in this area, including discussion of the Educators’ conference

09.00 Development of a national evaluation of the Regional Evaluation of the Musculoskeletal System (REMS)
Dr David Coady, City Hospital Sunderland Foundation trust, Sunderland

09.50 An update on Arthritis Research UK education activities
Dr Inam Haq Arthritis Research UK and University of Brighton, Brighton and Mr Keir Windsor Arthritis Research UK, Chesterfield
### 09.00 – 10.30

**BHPR: Measuring disease activity in psoriatic arthritis**

*Chairs: Dr Michael Backhouse, University of Leeds, Leeds and Ms Kate Gadsby, Derby Hospitals Foundation Trust, Derby*

**Aim:**
To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques

**Outcome 1:**
Understand importance of measuring disease activity in the context of modern disease management

**Outcome 2:**
Gain practical experience of performing joint assessments

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td><strong>Measurement of disease activity in psoriatic arthritis and minimal disease activity</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Laura Coates, University of Leeds, Leeds</em></td>
</tr>
<tr>
<td>09.20</td>
<td><strong>Assessing disease activity: instructions on aspects of minimal disease activity</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Laura Coates, University of Leeds, Leeds</em></td>
</tr>
<tr>
<td>09.30</td>
<td><strong>Assessing disease activity workshop on minimal disease activity</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Laura Coates, University of Leeds, Leeds, Dr Victoria Chamberlain, Trafford General Hospital, Manchester and Dr David Pickles, Chapel Allerton Hospital, Leeds</em></td>
</tr>
<tr>
<td>10.00</td>
<td><strong>NAPSI: Nail psoriasis severity index</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr David Pickles, Chapel Allerton Hospital, Leeds</em></td>
</tr>
<tr>
<td>10.15</td>
<td><strong>Interactive quiz</strong></td>
</tr>
<tr>
<td></td>
<td><em>Dr Michael Backhouse, University of Leeds, Leeds</em></td>
</tr>
</tbody>
</table>

### 10.30 – 11.30

**Poster viewing and exhibition | Tea and coffee**

**Categories**
- BHPR: Audit and clinical evaluation
- BHPR Research: qualitative
- BHPR Research: quantitative
- Biology of bone, cartilage and connective tissue disease
- Education
- Osteoporosis and metabolic bone disease
- Paediatric and adolescent rheumatology
- Pain
- Primary Care
- SLE and antiphospholipid syndrome

**Poster Tours**
- BHPR
- SLE and antiphospholipid syndrome
- Education

### 10.30 – 11.00

**NEW – Innovation theatre: Roche**

Combination therapy in RA: Methotrexate debate  
*Prof Ernest Choy, University of Cardiff, Cardiff*

### 11.00 – 11.30

**NEW – Innovation theatre: Medac**

Early aggressive use of subcutaneous methotrexate – financial and health benefits  
*Dr Sandeep Bawa, Gartnavel General Hospital, Glasgow*
### Essentials in rheumatology: Symptoms diagnosis and management

**Chairs:** Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College, London

**Aim:** A comprehensive update covering everything you need to know about changes in rheumatology

**Outcome 1:** To prepare rheumatologists for revalidation and provid a valuable educational opportunity for trainees

**Outcome 2:** Delegates will have had the opportunity to discuss symptom diagnosis

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Bursitis, enthesopathy and nerve entrapment</td>
</tr>
<tr>
<td>12.00</td>
<td>Autoantibodies</td>
</tr>
<tr>
<td>12.30</td>
<td>Improving patient management: Ready access to biological therapies</td>
</tr>
</tbody>
</table>

### Arthritis pain: mechanisms, meaning and medicines

**Chair:** Prof David Walsh, University of Nottingham, Nottingham

**Aim:** To update on the current understanding of the pathophysiology and psychology of pain in people with arthritis, and recent advances in its medical management

**Outcome 1:** Delegates will understand how the relationships between arthritis pain and joint pathology are complex, and how the way that we think about that relationship can have major impact on the development and use of effective analgesics

**Outcome 2:** Delegates will be better able to offer advice about medications and exercise, and be aware of novel approaches that may better improve arthritis pain in the near future

**Outcome 3:** Delegates will reflect on their own practice regarding what explanations they give patients of their pain, and how they should manage it

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Pathophysiology of arthritis pain peripheral and spinal mechanisms of osteoarthritis pain: experimental models</td>
</tr>
<tr>
<td>12.00</td>
<td>Why does pain instil fear?</td>
</tr>
<tr>
<td>12.30</td>
<td>NGF inhibition as a strategy to treat musculoskeletal pain</td>
</tr>
</tbody>
</table>

### The emerging role of epigenetics in rheumatic diseases

**Chairs:** Prof Gerry Wilson, University of Sheffield, Sheffield and Prof Christopher Buckley, University of Birmingham, Birmingham

**Aim:** To provide an overview of the role of epigenetics in the pathogenesis of rheumatic diseases

**Outcome 1:** To understand the epigenetic mechanisms controlling gene expression

**Outcome 2:** To highlight current knowledge on the role of epigenetics in RA and OA

**Outcome 3:** To be aware of the potential of therapeutic targeting of the epigenetic signature

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Epigenetic influences in autoimmune rheumatic diseases</td>
</tr>
<tr>
<td>12.00</td>
<td>The epigenetic influences in osteoarthritis</td>
</tr>
<tr>
<td>12.30</td>
<td>Therapeutic targeting of the epigenome</td>
</tr>
</tbody>
</table>
### BHPR plenary orals

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker &amp; Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Clinical and cost-effectiveness of a multidisciplinary foot care programme for children and adolescents with juvenile idiopathic arthritis: an exploratory trial</td>
<td>Dr Gordon Hendry, University of Western Sydney, Penrith, Australia</td>
</tr>
<tr>
<td>11.45</td>
<td>Predictors of risk of foot ulceration occurring in people with rheumatoid arthritis (RA) without diabetes</td>
<td>Dr Jill Firth, University of Leeds, Leeds</td>
</tr>
<tr>
<td>12.00</td>
<td>“I’m being a better doctor”: training for clinicians to support self-management</td>
<td>Dr Emma Dures, Academic Rheumatology, Bristol</td>
</tr>
<tr>
<td>12.15</td>
<td>Widespread and regional pain predict social participation restriction in older adults: a prospective cohort study</td>
<td>Dr Ross Wilkie, Keele University, Keele</td>
</tr>
<tr>
<td>12.30</td>
<td>Quality of life over the first 5-years of RA: findings from the early rheumatoid arthritis network</td>
<td>Dr Sam Norton, King’s College London, London</td>
</tr>
<tr>
<td>12.45</td>
<td>Scottish society of rheumatology (SSR) occupational therapy rheumatoid arthritis (RA) work audit</td>
<td>Mrs Janet Harkess, NHS Fife, Kirkcaldy</td>
</tr>
</tbody>
</table>

### Oral abstracts: Primary care

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker &amp; Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Transcutaneous electrical nerve stimulation for the management of tennis elbow: a pragmatic randomized controlled trial</td>
<td>Dr Linda Chesterton, Keele University, Keele</td>
</tr>
<tr>
<td>11.45</td>
<td>Gout is an independent risk factor for all types of vascular disease: a retrospective cohort study in the UK general practice research database (GPRD)</td>
<td>Dr Lorna Clarson, Keele University, Keele</td>
</tr>
<tr>
<td>12.00</td>
<td>Case-finding for osteoporosis and fracture in primary care</td>
<td>Dr Jane Gibson, NHS Fife, Kirkcaldy</td>
</tr>
<tr>
<td>12.15</td>
<td>Development of a model consultation and training package for practice nurses to support self-management of patients consulting with osteoarthritis in primary care</td>
<td>Dr Emma Healey, Keele University, Keele</td>
</tr>
<tr>
<td>12.30</td>
<td>Rocker sole shoes are no more beneficial than flat sole shoes in the management of chronic low back pain</td>
<td>Dr Sian MacRae, King’s College London, London</td>
</tr>
<tr>
<td>12.45</td>
<td>The risk of a subsequent cancer diagnosis after PMR: a primary care database study</td>
<td>Dr Sara Muller, Keele University, Keele</td>
</tr>
</tbody>
</table>

### SIG: MSK disorders in ethnic minorities

**Chair:** Prof Kuntal Chakravarty, Queen’s Hospital, Essex

- **Aim:**
  - To understand the metabolism and usefulness of Vitamin D in musculoskeletal disorders with emphasis on ethnic minorities
  - To improve the understanding of vitamin D deficiency
  - To improve the therapeutic challenges
  - To develop research agendas

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker &amp; Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Vitamin D: its different facets</td>
<td>Dr Trpkovic, Guildford University, Surrey</td>
</tr>
<tr>
<td>12.00</td>
<td>Research in the vitamin D deficiency in minority population</td>
<td>Prof Mark Johnson, University of Leicester, Leicester</td>
</tr>
<tr>
<td>12.30</td>
<td>Research in vitamin deficiency</td>
<td>Dr Dipak Dutta, University of Manchester, Manchester</td>
</tr>
</tbody>
</table>
### SIG: Adolescent and young adult rheumatology
**Chairs:** Dr Alison Jordan, University Hospital Birmingham NHS Foundation Trust, Birmingham and Dr Liza McCann, Alder Hey Children’s Hospital, Liverpool

**Aim:** To update national clinical and academic picture in transitional rheumatology in key conditions that commence in childhood

**Outcome 1:** To gain updates in the increasing evidence supporting the transition of adolescents into adult services. Clinical and psychosocial outcomes

**Outcome 2:** To gain understanding in the different viewpoints clinically and academically of adolescent SLE from paediatric and adult experts

**Outcome 3:** To update on the pathophysiological understanding and clinical outcomes of adolescents and young adults with MAS/HLH

**11.30** *Meeting at the edge: a paediatric and adult view of SLE in the adolescent years*
*Prof David Isenberg, University College London, London, and Dr Michael Beresford, Alder Hey Children’s Hospital, Liverpool*

**12.00** *Pathophysiology of teenage/young adult myositis: what have we learnt?*
*Prof Lucy Wedderburn, University College London, London*

**12.20** *MAS/HLH: current understanding and management in adolescents and young adults*
*Dr A Ramanan, Bristol Royal Hospital for Children, Bristol*

**12.50** *Adolescent Rheumatology Research Network*
*Prof Lucy Wedderburn, University College London, London*

### SIG: Ultrasound
**Chair:** Dr Zunaid Karim, Mid Yorkshire NHS Trust, Pontefract

**Aim:** To allow for those around the UK with a specialist interest in ultrasound to meet and update each other with regard to training programmes for ultrasound, course development and registrar training needs in ultrasound

**Outcome 1:** Delegates will be aware of new developments in BSR ultrasound courses, where they will be held and the agreed outline for future courses

**Outcome 2:** Delegates will be informed of results of a questionnaire of rheumatology trainees thoughts on ultrasound training requirements

**Outcome 3:** Delegates will have update from specific training programmes in Yorkshire and Scotland

**11.30** *STR’s perspective on ultrasound training needs, food for thought*
*Dr Rainer Klocke, Dudley NHS Foundation Trust, Dudley*

**12.00** *Developing skills in ultrasound course*
*Dr Cristina Estrach, University Aintree Hospital NHS Foundation Trust, Liverpool*

**12.30** *Ultrasound anatomy course, new developments and possible future ultrasound injection course*
*Dr David Wright, City Hospitals Sunderland NHS Foundation Trust, Sunderland*

### 13.00 – 14.00 Exhibition | Lunch

### BSR AGM

Join your colleagues and meet the Trustees, Regional Chairs and committee members of your society. Hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. Your attendance is highly valued and tasty lunch bags will be provided.
### Essentials in Rheumatology: Clinical Decision Making

**Aim:** A comprehensive update covering everything you need to know about changes in rheumatology

**Outcome 1:** To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees

**Outcome 2:** Delegates will have had their clinical decision making skills tested

- **14.30**
  - **Pregnancy**
  - **Prof Lesley Regan, Imperial College London, London**

- **15.15**
  - **Lupus**
  - **Dr David D’Cruz, St Thomas’ Hospital, London**

### BSR/BHPR: Long-standing Musculoskeletal Pain: Impact, Perceptual Representations and Treatment

**Aim:** To provide delegates with an understanding of how long-standing musculoskeletal pain affects both society and the individual and learn how novel approaches have exciting potential in rheumatology

**Outcome 1:** Recognise societal impact and disease burden of long-standing musculoskeletal pain

**Outcome 2:** Understand how the perceptual representation of the body in pain can impact on function, and how this can be manipulated for therapeutic effect

**Outcome 3:** Understand the principles of graded exposure therapy (a psychological/functional approach) and how it may be clinically effective in treating pain

- **14.30**
  - **Musculoskeletal pain - the societal burden**
  - **Dr Gareth Jones, University of Aberdeen, Aberdeen**

- **15.00**
  - **Musculoskeletal pain - perceptual representations of the painful body**
  - **Dr Jenny Lewis, Royal National Hospital for Rheumatic Disease NHS Foundation Trusts, Bath**

- **15.30**
  - **Graded exposure in vivo for CRPS-I**
  - **Dr Marlies den Hollander, Maastricht University, Maastricht, The Netherlands**

### Adolescent and Young Adult Rheumatology

**Aim:** To provide adult rheumatologists and health professionals who care for young adults and/or adolescents with child onset rheumatological conditions with an overview of current best practice in key areas

**Outcome 1:** Delegates will have an update on current understanding evidence based on optimal therapeutic management and outcomes of young adults who have arthritis that commenced in childhood

**Outcome 2:** Delegates will gain insight into psychosocial impact of JIA on the adolescent and parent and current practice on how to use this knowledge to improve outcomes

**Outcome 3:** Delegates will gain updated knowledge concerning the clinical approach of treating adolescents and young adults with childhood onset myositis

- **14.30**
  - **Young adults with child onset arthritis: how our current understanding of the disease and management affect physical and psychosocial outcomes**
  - **Dr John Ioannou, University College Hospital, London**

- **14.50**
  - **Psychosocial challenges of teenagers/young adults with JIA: can adolescents/young adults be persuaded to ‘take the medicine?’**
  - **Speaker to be announced**

- **15.10**
  - **Psychosocial challenges of teenagers/young adults with JIA: direct and indirect effect of parenting behaviour on older teenagers with JIA – help or hindrance?**
  - **Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath**

- **15.30**
  - **How to manage adolescent onset myositis in teenagers and young adults**
  - **Dr Clarissa Pilkington, Great Ormond Street Hospital, London**
### BHPR: Clinical update on axial spondyloarthropathy (ASpA)
**Chairs:** Mrs Susan Gurden, St Woolos Hospital, Newport and Ms Lindsey Hooper, University of Southampton, Southampton

**Aim:**
To provide an overview on current thinking on classification of Inflammatory back pain, recognition, assessment and implementation of treatment, monitoring and management strategies

**Outcome 1:**
To discuss issues and uncertainties in diagnostic recognition and onward management of inflammatory back pain

**Outcome 2:**
To highlight the implications of psychological status on subjective assessments and awareness of the importance of inter and intra operator reliability when completing BASMI assessment

**Outcome 3:**
To introduce the concept and implementation of negotiated monitoring and management strategies, to raise awareness and understanding of specific patient needs within the multidisciplinary team

14.30  **Advances in the diagnosis and management of ‘Axial SpA’**  
*Dr Stefan Siebert, Princess of Wales Hospital, Glasgow*

15.00  **Current assessment in ankylosing spondylitis and the importance of a biopsychosocial approach**  
*Dr Jane Martindale, Wightington Wigan and leight NHS Foundation Trust, Lancashire*

15.30  **Ankylosing Spondylitis: personal care plan**  
*Mr Colin Beevor, Queen Alexandra Hospital, Portsmouth and Ms Claire Jeffries, Queen Alexandra Hospital, Cosham*

### Oral abstracts: OA and metabolic bone disease

14.30  **Maternal milk intake is associated with increased offspring bone mineral content**  
*Dr Zoe Cole, MRC Lifecourse Epidemiology Unit, Southampton*

14.45  **Bisphosphonate use and improved implant survival: a nation-wide cohort study**  
*Dr Daniel Prieto-Alhambra, Green Templeton College, Oxford*

15.00  **Mortality following elective total hip replacement and hip resurfacing**  
*Dr Andrew Judge, University of Oxford, Oxford*

15.15  **Effect of strontium ranelate on knee pain in osteoarthritis: a responder analysis**  
*Prof Cyrus Cooper, MRC Lifecourse Epidemiology Unit, Southampton*

15.30  **Predictors of poor long-term outcome in physical function following TKA**  
*Dr Amit Kiran, University of Oxford, Oxford*

15.45  **Pegloticase for refractory gout: efficacy and safety summary of the GOUT1 and GOUT2 phase 3 trials**  
*Dr Faith Ottery, Savient Pharmaceuticals, Inc. New York, United States of America*

### ARMA
**Chair:** Mr Federico Moscogiuri, ARMA, London

**Aim:**
Discuss and identify ways to ensure that MSK services reflect local population needs via the development of MSK clinical networks

**Outcome 1:**
Present and ‘test out’ work done by ARMA on clinical networks to date via its strategic partnership with the DH

**Outcome 2:**
Identify key challenges in establishing and supporting effective MSK clinical networks

**Outcome 3:**
Identify examples of existing good practice and means of disseminating this with key stakeholders and call to action

14.30  **Introduction**  
*M Mr Federico Moscogiuri, ARMA, London*

14.40  **The State of musculoskeletal disorders (MSDs) in the NHS**  
*Dr Chris Deighton, Derby Hospitals NHS Trust, Derby*

14.55  **Making it happen: how clinical networks can provide a solution**  
*Dr Alan Nye, Pennine MSK Partnership Ltd, Oldham*

15.10  **Examples of good practice**  
*Ms Debbie Cook, CEO NASS – National Ankylosing Spondylitis Society, Surrey*

15.25  **Interactive panel discussion with question and answer session**  
*M Mr Federico Moscogiuri, ARMA, London*
### SIG: SLE

**Chair:** Prof Ian Bruce University of Manchester, Manchester

#### Aim:
To learn about the range of neuropsychiatric manifestations associated with SLE and consider how to develop a differential diagnosis and management plan for such patients.

#### Outcome 1:
To understand the range of neuropsychiatric manifestations in SLE.

#### Outcome 2:
To develop a strategy to investigate neuropsychiatric manifestations in SLE patients.

#### Outcome 3:
To learn about management options in patients across the range of neuropsychiatric manifestations in SLE.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:30 | An overview of the clinical presentation and manifestations of neuropsychiatric lupus  
Prof John G Hanly, Dalhousie University, Halifax, Nova Scotia |
| 14:50 | Assessment of neuropsychiatric manifestations of SLE: a neurologist’s viewpoint  
Dr Michael Zandi, University of Cambridge, Cambridge |
| 15:15 | Assessment of neuropsychiatric manifestations of SLE: a psychiatrist’s viewpoint  
To be announced |
| 15:35 | EULAR guidelines on the management of neuropsychiatric manifestations of SLE  
Dr George Bertsias, University of Crete, Greece |

### BHPR: Measuring disease activity in RA, when is your patient is in remission

**Chair:** Dr Michael Backhouse, University of Leeds, Leeds

#### Aim:
To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques.

#### Outcome 1:
Understand importance of measuring disease activity in the context of modern disease management.

#### Outcome 2:
Gain practical experience of performing joint assessments.

#### Outcome 3:
Update on role of imaging in assessing disease activity.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 14:30 | Why measure disease activity and what should we aim to achieve?  
Prof Peter Taylor, University of Oxford, Oxford |
| 14:50 | Assessing disease activity: workshop instructions on DAS Scoring  
Dr Jill Firth, University of Leeds, Leeds |
| 15:00 | Assessing disease activity in RA  
Dr Jill Firth, University of Leeds, Leeds, Dr Victoria Chamberlain, Trafford Healthcare NHS Trust, Manchester and Dr David Pickles, Chapel Allerton Hospital, Leeds |
| 15:30 | The role of imaging in assessing disease activity  
Prof Peter Taylor, University of Oxford, Oxford |
| 15:45 | Interactive quiz  
Dr Michael Backhouse, University of Leeds, Leeds |

#### Heberden Oration
The changing face of rheumatoid arthritis: A palindromic shift  
Prof Paul Emery, University of Leeds, Leeds
Industry supported symposia catering

Industry supported symposia: Abbott
Advances in ultrasound and MRI imaging in rheumatology
Chair: Prof Paul Emery, University of Leeds, Leeds

Aim:
To provide delegates with an overview of the key advances in ultrasound and MR imaging in the management of inflammatory arthritis and update on best practice

Outcome 1:
Delegates will be able understand the key issues in the application of ultrasound in rheumatoid arthritis clinical practice

Outcome 2:
Delegates will be able understand the key issues in the application of magnetic resonance imaging in spondyloarthritis clinical practice

State of the art ultrasound imaging: today and tomorrow
Dr Cristina Estrach, Aintree University Hospital NHS Foundation Trust, Liverpool
A targeted ultrasound approach to remission in RA including TURA study
Prof Paul Emery, University of Leeds, Leeds
Redefining standards of care in SpA with the use of MRI
Dr Alex Bennett, Defence Medical Rehabilitation Centre, Headley Court

Conference Dinner
With a lively and diverse culture, Birmingham has a never ending offering of delicious restaurants to try, none better than the popular Shimla Pinks. BSR and BHPR invites guests to carry on networking into the night at this award winning restaurant, enjoy!
**Thursday 25 April 2013**

### Industry supported symposia catering

#### Industry supported symposia: Bristol-Myers Squibb

**Getting it right first time – Biologics in RA; a debate**  
*Chair to be announced*

<table>
<thead>
<tr>
<th>Aim:</th>
<th>Rheumatologists and allied health professionals managing Rheumatoid Arthritis (RA) have an ever expanding range of treatment options available for the treatment of RA, however it can be challenging to ensure that these therapies are used in a way that offers the best patient outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome 1:</td>
<td>The audience will be able to compare and contrast the differing mechanisms of action and optimal use of biologic therapies in patient-centric treatment of RA</td>
</tr>
<tr>
<td>Outcome 2:</td>
<td>The audience will be able to better understand the latest direct head-to-head comparison studies of biologic therapies for the treatment of RA</td>
</tr>
<tr>
<td>Outcome 3:</td>
<td>The audience will be able to recognise the impact of choosing appropriate, effective early treatment in order to deliver tight-control on long-term patient outcomes in RA</td>
</tr>
</tbody>
</table>

**Current understanding of RA and its aetiology: how can the different MOA’s of the biologics be used to deliver patient outcomes?**  
*Prof Peter Taylor, University of Oxford, Oxford*

**The latest data in the treatment of RA with Biologic therapies: what do the latest head-to-head trials tell us about Biologic Therapies and their place in RA treatment?**  
*Dr Andrew Ostor, Addenbrookes Hospital, Cambridge*

**What do know, where are we heading – getting it right 1st time, debating the facts**  
*Chairman, speakers and panel*

### Ageing and the musculoskeletal system

**Chairs:** Dr Fraser Birrell, University of Newcastle, Newcastle and Prof Tim Cawston, University of Newcastle, Newcastle

<table>
<thead>
<tr>
<th>Aim:</th>
<th>The ageing population and high prevalence of age associated musculoskeletal disease make it important that clinicians and researchers keep abreast of the latest research in this field</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome 1:</td>
<td>Delegates will understand the concept of healthy ageing</td>
</tr>
<tr>
<td>Outcome 2:</td>
<td>Delegates will know the state of the art of work with animal models and stem cells</td>
</tr>
<tr>
<td>Outcome 3:</td>
<td>Delegates will recognise the occurrence of age related musculoskeletal disease and the challenges inherent in clinical trials in the elderly</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.00 | Musculoskeletal ageing: from epidemiology to clinical trials  
*Prof Cyrus Cooper, University of Southampton, Southampton* |
| 09.30 | Mouse models for mechanistic studies of skeletal muscle ageing  
*Dr Aphrodite Vasilaki, University of Liverpool, Liverpool* |
| 10.00 | Stem cells and ageing  
*Dr Illaria Belluantonio, University of Sheffield, Sheffield* |

### Ask the experts

**Chairs:** Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 09.00 | SLE  
*Prof Ian Bruce, University of Manchester, Manchester and Prof Anisur Rahman, University College, London* |
### Mortality in rheumatic disease

**Chairs:** Prof Gary Macfarlane, University of Aberdeen, Aberdeen and Dr Jennifer Hamilton, Queen Elizabeth Hospital, Gateshead

| **Aim:** | To summarise the evidence on whether patients with specific rheumatic diseases experience excess mortality and if so to describe the specific causes of death in excess, possible mechanisms and relevance to management |
| **Outcome 1:** | To be able to describe the pattern of mortality associated with three musculoskeletal conditions |
| **Outcome 2:** | To understand the mechanisms underlying association with excess mortality |
| **Outcome 3:** | To understand the relevance of such patterns of excess mortality for managing patients with specific rheumatic diseases |

- **09.00** Mortality in systemic sclerosis: a European perspective  
  *Prof Ulf Müller-Ladner, Justus-Liebig University Giessen, Bad Nauheim, Germany*

- **09.30** Co-morbidities in RA and their influence on premature mortality  
  *Dr Nicola Gullick, King's College London Hospital, London*

- **10.00** Musculoskeletal pain and excess mortality: the story so far  
  *Dr Kelvin Jordan, Keele University, Keele*

### BSR/BHPR: Advanced practice in osteoarthritis

**Chairs:** Prof Philip Conaghan, University of Leeds, Leeds and Prof Michael Hurley, Kingston University and St George’s, University of London, London

| **Aim:** | This multidisciplinary will provide delegates with an overview of how aspects of advanced practice e.g. gait analysis, diagnostic ultrasound can be incorporated into the management pathways for patients with OA |
| **Outcome 1:** | Delegates will be able to understand how adverse mechanics influence structure and function at key sites in the lower limb and the implications for OA |
| **Outcome 2:** | Delegates will gain an insight into how research and clinical care can be integrated to impact positively on the care of patients with OA pathways for patients with symptomatic OA |
| **Outcome 3:** | Delegates will have a better understanding of how mechanical and imaging assessments impact on care |

- **09.00** The assessment of adverse mechanics in knee OA  
  *Prof Martijn Steultjens, Glasgow Caledonian University, Glasgow*

- **09.30** Amsterdam outpatient osteoarthritis clinic: integrating care and science for OA  
  *Dr Martin van der Esch, Reade Rehabilitation Centre, Amsterdam, The Netherlands*

- **10.00** The ULTRASCOT (ULTRAsound SCanning of Osteoarthritis in the Thumb) study: results and implications for practice  
  *Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow*

### Oral abstracts: RA clinical

- **09.00** Long-term outcomes of early RA patients initiated with adalimumab plus methotrexate compared with methotrexate alone following a targeted treatment approach  
  *Prof Paul Emery, University of Leeds, Leeds*

- **09.15** 24 week results of a blinded phase 2B dose-ranging study of baricitinib, an oral jak1/jak2 inhibitor, in combination with traditional DMARDs in patients with rheumatoid arthritis  
  *Dr Peter Taylor, University of Oxford, Oxford*

- **09.30** Tocilizumab (TCZ) monotherapy compared with adalimumab (ADA) monotherapy in RA: results of a 24 week study  
  *Speaker to be announced*

- **09.45** Head-to-head comparison of subcutaneous abatacept versus adalimumab in the treatment of rheumatoid arthritis: key efficacy and safety results from the ample (abatacept versus adalimumab comparison in biologic-naive RA subjects with background methotrexate  
  *Dr Michael Maldonado, Bristol-Myers Squibb, Princeton, United States of America*

- **10.00** What happens to ACPA positive patients without clinical synovitis?  
  *Dr Chadi Rakieh, University of Leeds, Leeds*

- **10.15** Interferon gene expression signature in neutrophils from RA patients pre and post anti-TNF therapy  
  *Dr Helen Wright, University of Liverpool, Liverpool*
### SIG: Heritable disorders of connective tissue

**Chair:** Prof Rodney Grahame, University College Hospital, London and Prof Howard Bird, University of Leeds, Leeds

**Aim:**
To familiarise BSR and BHPR members and guests with the work of Ehlers-Danlos National Diagnosis Service (funded by the National Commissioning Group) and to assess its progress since its inception in 2010

**Outcome 1:** Acquisition of knowledge of the role of molecular genetic testing in the differential diagnosis of the rare forms of EDS

**Outcome 2:** Acquisition of knowledge of Novel COL3A1 collagen mutations and their EDS phenotypes

**Outcome 3:** Acquisition of knowledge of rheumatological complications in rare genetic syndromes

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>New observations on EDS in South Africa</td>
<td>Prof Peter Beighton, University of Cape Town, South Africa</td>
</tr>
<tr>
<td>09.15</td>
<td>Novel COL3A1 mutations in Vascular EDS phenotypes (the London experience since 2009)</td>
<td>Prof Mike Pope, Nortwich Park and St Marks Hospitals, Harrow</td>
</tr>
<tr>
<td>09.30</td>
<td>The EDS National Diagnostic Service in 2013</td>
<td>Dr Glenda Sobey, Sheffield Children’s Hospital, Sheffield</td>
</tr>
<tr>
<td>09.45</td>
<td>Molecular Genetic Diagnosis in EDS</td>
<td>Dr Mandy Nesbitt, Sheffield Children’s Hospital, Sheffield</td>
</tr>
<tr>
<td>10.00</td>
<td>Rare Mendelian disorders and Joint Hypermobility Syndrome</td>
<td>Dr Anthony Vandersteen, Northwick Park and St Marks Hospitals, Harrow</td>
</tr>
<tr>
<td>10.15</td>
<td>Question and answer session</td>
<td></td>
</tr>
</tbody>
</table>

### SIG: Sjögren’s

**Chair:** Dr Elizabeth Price, Great Western Hospital, Swindon

**Aim:**
To update and educate rheumatologists on the practical management of and recent advances in Sjögren’s syndrome

**Outcome 1:** Update management of dry eye in Sjögren’s syndrome

**Outcome 2:** Update management of dry mouth in Sjögren’s syndrome

**Outcome 3:** Update on new therapeutic advances in the systemic management of Sjögren’s syndrome

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>The modern management of dry eye in Sjögren’s syndrome</td>
<td>Miss Saaesha Rauz, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>09.25</td>
<td>The modern management of dry mouth in Sjögren’s syndrome</td>
<td>Mr John Hamburger, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>09.50</td>
<td>New therapeutic approaches for Sjögren’s</td>
<td>Dr Francesca Barone, University of Birmingham, Birmingham</td>
</tr>
</tbody>
</table>
**BHPH: Introducing cognitive behaviour approaches to rheumatic disease: top tips and tools for clinic**

**Aim:**
To introduce rheumatology clinicians to basic cognitive-behavioural (CB) techniques and tools that can be readily integrated into routine clinical encounters, provide opportunities to observe demonstrations, and for delegates to practice the skills in small groups.

**Outcome 1:**
Learn how to work on a formulation diagram with patients to identify and understand the links between thoughts, feelings, and behaviours, and how they relate to symptoms.

**Outcome 2:**
Learn how to support patients to set effective goals by identifying components of SMART goals; including how and where to start, follow up, and build on goals, and suggestions for constructive responses when goals are not achieved.

**Outcome 3:**
Learn how to use Socratic questioning to unpick behavior patterns in relation to activity, sleep, and rest; and review self-monitoring records with patients to identify where changes can be made and further support is needed.

---

**09.00**
**Cognitive-behavioural approaches to rheumatic disease: tools for clinic**
*Dr Emma Dures, Bristol Royal Infirmary, Bristol*

**09.15**
**The impact of symptoms: making a cognitive-behavioural formulation**
*Mrs Elizabeth Hale, Russells Hall Hospital, Dudley and Dr Marianne Morris, University of the West of England, Bristol*

**09.35**
**Effective goal setting in the rheumatology clinic**
*Prof Sarah Hewlett, Bristol Royal Infirmary, Bristol and Dr Claire Goodchild, Institute of Psychiatry, London*

**09.55**
**Activity, rest and sleep: understanding behaviour patterns**
*Dr Nicholas Ambler, Frenchay Hospital, Bristol and Dr Emma Dures, Bristol Royal Infirmary, Bristol*

---

**10.30 – 11.30**
**Poster viewing and exhibition | Tea and Coffee**

<table>
<thead>
<tr>
<th>Categories</th>
<th>Poster Tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>Cell receptor-ligand interaction, signalling, activation and apoptosis</td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>Cytokines and inflammatory mediators</td>
<td>Spondyloarthropathy</td>
</tr>
<tr>
<td>Epidemiology</td>
<td></td>
</tr>
<tr>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>Health services research, economics and outcomes research</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous rheumatic diseases</td>
<td></td>
</tr>
<tr>
<td>Muscle Disorders</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: clinical features</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: pathogenesis and animal models</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: treatment</td>
<td></td>
</tr>
<tr>
<td>Scleroderma and related disorders</td>
<td></td>
</tr>
<tr>
<td>Sjögren’s syndrome and other connective tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Soft tissue and regional musculoskeletal disease, fibromyalgia</td>
<td></td>
</tr>
<tr>
<td>Spondylarthropathies (including psoriatic arthritis)</td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
</tr>
</tbody>
</table>

---

**10.30 – 11.30**
**NEW – Innovation theatre: Celgene**

Looking inside the cell for a new perspective on psoriatic arthritis
*Prof Miles D Houslay, Chair of Pharmacological Innovation, Institute of Pharmaceutical Science, King’s College London, London and Prof Oliver Fitzgerald, Newman Clinical Research Professor, School of Medicine and Medical Science, St Vincent’s Hospital, Dublin, Ireland*
## Oral abstracts: Science

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>The role of protein kinase D signalling in the induction of matrix metalloproteinases in human articular chondrocytes</td>
<td>Mr Jonathan Baker, University of Newcastle, Newcastle</td>
</tr>
<tr>
<td>11.45</td>
<td>Effects of PTPN22 R620W on neutrophil function in health and disease</td>
<td>Ms Rachel Bayley, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>12.00</td>
<td>Macrophage metabotypes in the hypoxic inflammatory environment assessed using metabolomic profiling</td>
<td>Mr Martin Fitzpatrick, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>12.15</td>
<td>Synovial fibroblasts shape the recruitment and migration patterns of lymphocytes during resolving and persistent arthritis</td>
<td>Dr Helen McGettrick, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>12.30</td>
<td>Biological roles of C5orf30 in rheumatoid arthritis</td>
<td>Dr Munitta Muthana, University of Sheffield, Sheffield</td>
</tr>
<tr>
<td>12.45</td>
<td>Autocitrullinated porphyromonas gingivalis peptidylarginine deiminase: a novel antigen with potential for breaching immunologic tolerance in rheumatoid arthritis</td>
<td>Dr Anne-Marie Quirke, University of Oxford, Oxford</td>
</tr>
</tbody>
</table>

## Interactive clinical teaching: osteoporosis

Aim: To provide trainees with up-to-date clinical teaching on osteoporosis

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Osteoporosis: where are we now?</td>
<td>Prof Bill Fraser, University of East Anglia, Norwich</td>
</tr>
<tr>
<td>12.15</td>
<td>Osteoporosis: what don’t we know?</td>
<td>Prof Cyrus Cooper, University of Southampton, Southampton</td>
</tr>
</tbody>
</table>

## Polymyalgia rheumatic and giant cell arthritis

Aim: Update on diagnosis, investigations, treatment and research advances in PMR and GCA

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Classification criteria and guidelines for PMR</td>
<td>Prof Bhaskar Dasgupta, Southend University Hospital, Essex</td>
</tr>
<tr>
<td>12.00</td>
<td>Polymyalgia rheumatica: the view from primary care</td>
<td>Prof Christian Mallen, Keele University, Keele</td>
</tr>
<tr>
<td>12.20</td>
<td>Imaging for large vessel vasculitis in PMR and GCA</td>
<td>Prof Justin Mason, Imperial College London, London</td>
</tr>
<tr>
<td>12.40</td>
<td>Therapy update and clinical trials for PMR</td>
<td>Dr Victor Martinez-Taboada, Santander, Cantabria, Santander - Cantabria, Spain</td>
</tr>
</tbody>
</table>
### 11.30 – 13.00 Droitwich Lecture and prizes

**Chair:** Mr Robert Field, President BHPR

- **11.30**
  - In defence of non-evidence based medicine
    - *Dr Philip Helliwell, University of Leeds, Leeds*
  - **12.15**
    - Prize ceremony

### 11.30 – 13.00 Oral abstracts: Genetics

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Musculoskeletal pain is associated with BMI through shared genetic factors</td>
<td><em>Dr Frances Williams, King’s College London, London</em></td>
</tr>
<tr>
<td>11.45</td>
<td>Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models</td>
<td><em>Dr Darren Plant, University of Manchester, Manchester</em></td>
</tr>
<tr>
<td>12.00</td>
<td>Genes contributing to pain sensitivity in the normal population: an exome sequencing study</td>
<td><em>Dr Frances Williams, King’s College London, London</em></td>
</tr>
<tr>
<td>12.15</td>
<td>Ankylosing spondylitis is strongly associated with variants in the CMG2 gene</td>
<td><em>Ms Tugce Karaderi, University of Oxford, Oxford</em></td>
</tr>
<tr>
<td>12.30</td>
<td>A pilot study evaluating mRNA transcription profiles in idiopathic inflammatory and inclusion body myositis: a next generation sequencing approach</td>
<td><em>Dr Philip Hamann, Royal National Hospital for Rheumatic Diseases, Bath</em></td>
</tr>
<tr>
<td>12.45</td>
<td>The development of peripheral joint erosions and radiographic sacroiliitis has striking association with certain HLA alleles and haplotypes: genotype-phenotype correlation of 283 consecutive Psoriatic Arthritis patients</td>
<td><em>Dr Muhammad Haroon, St Vincent’s University Hospital, Dublin</em></td>
</tr>
</tbody>
</table>

### 11.30 – 13.00 SIG: Scleroderma

**Chair:** Prof Christopher Denton, University College London, London

**Aim:**
Update on management recommendations for SSc that are being developed and updated via EULAR, UKSSG and BSR. Implications for service provision in UK, shared care and specialist commissioning. Specific review of current best practice approaches to parenchymal involvement.

**Outcome 1:**
Participants will be up-to-date on current status of evidence and expert opinion based recommendations for management of SSc

**Outcome 2:**
Current best practice management of cardiac disease and lung fibrosis in SSc will be reviewed

**Outcome 3:**
New methods for objective assessment of Raynaud’s phenomenon and digital vascular disease will be presented

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>Integrated management recommendations for systemic sclerosis (scleroderma)</td>
<td><em>Prof Christopher Denton, University College London, London</em></td>
</tr>
<tr>
<td>11.45</td>
<td>Current approaches to management of lung fibrosis in scleroderma</td>
<td><em>Dr Bridget Griffiths, Freeman Hospital, Newcastle</em></td>
</tr>
<tr>
<td>12.10</td>
<td>Assessment and treatment of cardiac involvement</td>
<td><em>Dr Maya Buch, University of Leeds, Leeds</em></td>
</tr>
<tr>
<td>12.35</td>
<td>Objective non-invasive assessment of digital vascular disease</td>
<td><em>Dr Andrea Murray, University of Manchester, Manchester</em></td>
</tr>
</tbody>
</table>
### Thursday 25 April 2013

#### 11.30 – 14.00

**SIG: Soft tissue rheumatism and sports medicine**

*Chair: Dr Tim Jones, Defence Medical Rehabilitation Centre Headley Court, Surrey*

<table>
<thead>
<tr>
<th>Aim:</th>
<th>To provide a forum for discussion about the diagnosis and treatment of musculoskeletal and sports injuries and the benefits of exercise</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome 1:</td>
<td>Presentation on the recent Royal College report into the benefits of exercise in health and disease</td>
</tr>
<tr>
<td>Outcome 2:</td>
<td>An overview of the musculoskeletal injuries and conditions commonly found in professional dancers</td>
</tr>
<tr>
<td>Outcome 3:</td>
<td>A forum to discuss the future aims and organisation of the SIG in soft tissue rheumatism and sports medicine</td>
</tr>
</tbody>
</table>

11.30 ‘Exercise for life’ The Royal College of Physicians 2012 report and recommendations for physical activity in health and disease  
*Col John Etherington, Defence Medical Rehabilitation Centre Headley Court, Surrey*

12.00 Musculoskeletal injuries in dancers  
*Dr Roger Wolman, Royal National Orthopaedic Hospital, Stanmore*

12.30 Forum to discuss the aims of the SIG in musculoskeletal and sports medicine  
*Dr Tim Jones, Defence Medical Rehabilitation Centre Headley Court, Surrey*

#### 13.00 – 13.30

**NEW – Innovation theatre: Abbott**

Identifying diagnostic SpA lesions using MRI  
*Dr Alex Bennett, Defence Medical Rehabilitation Centre Headley Court, Surrey*

#### 13.00 – 14.00

**Exhibition | Lunch**

<table>
<thead>
<tr>
<th>Categories</th>
<th>Poster Tours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Science</td>
<td>Epidemiology</td>
</tr>
<tr>
<td>Cell receptor-ligand interaction, signalling, activation and apoptosis</td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>Cytokines and inflammatory mediators</td>
<td>Spondyloarthritis</td>
</tr>
<tr>
<td>Epidemiology</td>
<td></td>
</tr>
<tr>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>Health services research, economics and outcomes research</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous rheumatic diseases</td>
<td></td>
</tr>
<tr>
<td>Muscle Disorders</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: clinical features</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: pathogenesis and animal models</td>
<td></td>
</tr>
<tr>
<td>Osteoarthritis: treatment</td>
<td></td>
</tr>
<tr>
<td>Scleroderma and related disorders</td>
<td></td>
</tr>
<tr>
<td>Sjögren’s syndrome and other connective tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Soft tissue and regional musculoskeletal disease, fibromyalgia</td>
<td></td>
</tr>
<tr>
<td>Spondylarthropathies (including psoriatic arthritis)</td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td></td>
</tr>
</tbody>
</table>

**BHPR AGM**

Join your colleagues over a buffet lunch and meet BHPR Council members to hear what they have been doing on your behalf and how they plan to meet the challenges of the year ahead. This session follows on from the prestigious Droitwich Lecture and the annual Prize Awards; do stay on to congratulate the deserving prize winners and find out how you can get more involved in BHPR. Your attendance is highly valued.

**RATs AGM**
Standards, Audit and Guidelines working group open meeting

**Aim:**
To increase awareness of national audits and new BSR guidelines, promoting clinician engagement

**Outcome 1:**
Understanding and clinician engagement in the HQIP national audit of rheumatoid and early inflammatory arthritis

**Outcome 2:**
Awareness of new BSR clinical guidelines to support high quality care

**Outcome 3:**
Awareness of how to feedback comments on draft guidelines through open consultation

This session will give an overview of activities on guideline development, guideline accreditation and national audits. There will be presentations of new guidelines and the launch of open consultation on these.

Advances in cartilage biology: towards a better understanding of osteoarthritis

**Chair:** Prof Ian Clarke, University of East Anglia, Norwich

**Aim:**
To summarise recent advances in cartilage biology relevant to pathogenesis of osteoarthritis

**Outcome 1:**
Gain insight in novel molecular mechanisms of cartilage damage

**Outcome 2:**
Understand the importance of stability of the chondrocytes in osteoarthritis progression

**Outcome 3:**
Understand how homeostatic mechanisms can modify OA outcome and progression and how they could be harnessed for therapy

14.00 Role of injury and alarmins in osteoarthritis
Prof Wim Van den Berg, Radboud University Nijmegen, HC Nijmegen, The Netherlands

14.20 Calcium crystals and Ca++ pathways in the pathogenesis of osteoarthritis
Dr Jessica Bertrand, Muskuloskelettale Medizin, Munster, Germany

14.40 Targeting WNT signalling in osteoarthritis
Dr Francesco Dell’Accio, Queen Mary University of London, London

15.05 FGF signalling integrating biomechanics and cartilage homeostasis
Dr Tonia Vincent, University of Oxford, Oxford

Career development for new consultants

**Chairs:** Dr Benjamin Parker, University of Manchester, Manchester and Dr Sonia Panchal, Northampton General Hospital, Northampton

**Aim:**
To provide trainees with guidance and practical advice on how they may develop their careers as new consultants

**Outcome 1:**
To discuss the application process for consultant posts

**Outcome 2:**
To highlight the opportunities available to trainees to develop additional skills pre-CCT

**Outcome 3:**
Delegates will have a better understanding of the broader role of a new consultant

14.00 How to survive the consultant appointments process - and succeed!
Dr Neil Snowden, North Manchester General Hospital, Manchester

14.30 Becoming a consultant: tips from the front line
Dr Vinodh Devakumar, Royal Oldham Hospital, Oldham

15.00 Becoming a consultant: the extended role
Dr Nicholas Shenker, Addenbrookes Hospital, Cambridge
### Commissioning for rheumatology in a cold climate
**Chair:** Dr Chris Deighton, Derby Hospital NHS Trust, Derby

**Aim:**
The NHS reforms for commissioning have been implemented on 1st April 2013. Discuss and identify opportunities and threats for clinical and patient leadership in commissioning services such as rheumatology and how these can shape commissioning in the future plus key practical activities.

1. **Outcome 1:**
   What are the key issues that need to be addressed

2. **Outcome 2:**
   Identify opportunities for improving patients outcomes and values

3. **Outcome 3:**
   How can the clinical and patient voice most effectively influence policy and commissioners

4. **Outcome 4:**
   Identify practical improvements and innovations

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>The patient and clinical voice: may the force be with you</td>
<td>Mrs Ailsa Bosworth, NRAS - National Rheumatoid Arthritis Society, Berkshire</td>
</tr>
<tr>
<td>14.10</td>
<td>Developing the conditions for commissioning patient pathways that would deliver better value</td>
<td>Prof Paul Corrigan, Director of Strategy and Commissioning of the NHS London Strategic Health Authority, London</td>
</tr>
<tr>
<td>14.25</td>
<td>Commissioning clinical services in a cold climate</td>
<td>Mrs Laura Guest, British Society for Rheumatology, London</td>
</tr>
<tr>
<td>14.40</td>
<td>Better commissioning for service outcomes practical</td>
<td>Mr Philip Ainsworth, British Society for Rheumatology, London</td>
</tr>
<tr>
<td>14.55</td>
<td>Interactive question and answer session</td>
<td>Dr Chris Deighton, Derby Hospitals NHS Trust, Derby</td>
</tr>
</tbody>
</table>

### BHPR: The importance of health literacy in musculoskeletal disease
**Chairs:** Prof David Scott, Norfolk and Norwich University Hospitals, Norwich and Ms Cathy Ball, Imperial College London, London

**Aim:**
To provide an overview of the underpinning theory, evidence of effectiveness and strategies to enhance health literacy in patients with musculoskeletal disease.

1. **Outcome 1:**
   Attendees will be able to identify some of the background theories and evidence that contribute to the health literacy field

2. **Outcome 2:**
   Attendees will have an awareness of the issues contributing to enhancing health literacy and some communication techniques to support these

3. **Outcome 3:**
   Attendees will be aware of health literacy applications for their own practice

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>The evolving concept of health literacy and evidence from a systematic review of accessibility of arthritis patient education</td>
<td>Dr Wendy Lowe, University of Southampton, Southampton and Dr Jo Adams, University of Southampton, Southampton</td>
</tr>
<tr>
<td>14.30</td>
<td>The importance of health literacy in doctor patient communication</td>
<td>Dr Joanne Protheroe, Keele University, Keele</td>
</tr>
<tr>
<td>14.50</td>
<td>The importance of health literacy in patient engagement in marginalised groups</td>
<td>Prof Ade Adebajo, University of Sheffield, Sheffield and Ms Sandra Robinson, North Tyneside Hospital, Tyne and Wear</td>
</tr>
</tbody>
</table>
### Oral abstracts: Spondyloarthritis

14.00 – 15.30

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial</td>
<td>Prof Ade Adebajo, University of Sheffield, Sheffield</td>
</tr>
<tr>
<td>14.15</td>
<td>Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis with positive MRI of the sacroiliac joints or spine or elevated C-reactive protein at baseline</td>
<td>Dr Aileen Pangan, Abbott Laboratories, Illinois, Chicago</td>
</tr>
<tr>
<td>14.30</td>
<td>Spinal inflammation in the absence of SI joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis</td>
<td>Dr Aileen Pangan, Abbott Laboratories, Illinois, Chicago</td>
</tr>
<tr>
<td>14.45</td>
<td>Disease burden is comparable in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis</td>
<td>Speaker to be announced</td>
</tr>
<tr>
<td>15.00</td>
<td>Effectiveness of sequential biologic use in psoriatic arthritis: results of a large retrospective survey</td>
<td>Dr Meghna Jani, University of Manchester, Manchester</td>
</tr>
<tr>
<td>15.15</td>
<td>A proposed algorithm and its performance evaluation for the best referral by ophthalmologists of acute anterior uveitis patients with possible underlying spondyloarthropathy</td>
<td>Dr Muhammad Haroon, St Vincent’s University Hospital, Dublin</td>
</tr>
</tbody>
</table>

### SIG: Myositis

**Chairs:** Dr Hector Chinoy Salford Royal NHS Foundation Trust, Salford and Dr Patrick Gordon, Kings College Hospital, London

**Aim:** To provide an update on current issues in myositis and upcoming research/clinical activities

**Outcome 1:** To discuss the latest tools to be used in the diagnosis and differential diagnosis of myositis

**Outcome 2:** To discuss current paradigms in the treatment of inflammatory myositis

**Outcome 3:** To gain an understanding of the extramuscular manifestations in myositis

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Development of standards of treatment for adults with myositis and different phenotypes, STAMP</td>
<td>Dr Sarah Tansley, University of Bath, Bath</td>
</tr>
<tr>
<td>14.20</td>
<td>Summary from the Cochrane review for treatment of myositis</td>
<td>Dr Patrick Gordon, Kings College Hospital, London</td>
</tr>
<tr>
<td>14.40</td>
<td>Development of new classification criteria in myositis: the international myositis classification criteria project, IMCCP</td>
<td>Dr Hector Chinoy Salford Royal NHS Foundation Trust and Prof Robert Cooper, Salford Royal NHS Foundation Trust, Salford</td>
</tr>
<tr>
<td>15.05</td>
<td>Challenging myositis patients: case vignettes</td>
<td>Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol</td>
</tr>
</tbody>
</table>

### SIG: Rheumatoid arthritis

**Chair:** Mrs Janet Cushnaghan, Southampton General Hospital, Southampton

**Aim:** To provide delegates with topics of interest in the field of rheumatoid arthritis

**Outcome 1:** Delegates will increase their knowledge of the reasons for delay in presenting with arthritis symptoms

**Outcome 2:** Delegates will learn about the importance of examining the feet in rheumatoid arthritis

**Outcome 3:** Delegates will be able to participate in discussion around the topics presented

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker and Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Reasons for delay in presenting with arthritis symptoms</td>
<td>Dr Rebecca Stack, City Hospital, Birmingham</td>
</tr>
<tr>
<td>14.45</td>
<td>Joint inequalities: should the foot continue to be excluded from the DAS-28?</td>
<td>Dr Lindsay Hooper, Southampton General Hospital, Southampton</td>
</tr>
</tbody>
</table>
### BHPR: The use of ultrasound for nurses and allied health professionals

**Chairs:** Dr Richard Wakefield, University of Leeds, Leeds and Dr Deborah Turner, Glasgow Caledonian University, Glasgow

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/St (University, Location)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00</td>
<td>Training routes for nurses and AHPs in musculoskeletal ultrasound: practical considerations</td>
<td>Dr Catherine Bowen, University of Southampton, Southampton</td>
</tr>
<tr>
<td>14.20</td>
<td>The use of ultrasound to support research</td>
<td>Mrs Heidi Siddle, University of Leeds, Leeds</td>
</tr>
<tr>
<td>14.40</td>
<td>The use of ultrasonography in a physiotherapy led 'one stop' hand clinic</td>
<td>Mrs Mhairi Brandon, Glasgow Royal Infirmary, Glasgow</td>
</tr>
<tr>
<td>15.05</td>
<td>Ultrasound guided injections in rheumatology practice</td>
<td>Mrs Alison Hall, Cannock Chase Hospital, Cannock</td>
</tr>
</tbody>
</table>

### SIG: Genetics

**Chair:** Prof Anne Barton, University of Manchester, Manchester

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/St (University, Location)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Lessons from genetic fine mapping studies of rheumatoid arthritis</td>
<td>Dr Stephen Eyre, University of Manchester, Manchester</td>
</tr>
<tr>
<td>16.30</td>
<td>Lessons from GWAS of osteoarthritis: where do we go from here?</td>
<td>Prof John Loughlin, University of Newcastle, Newcastle</td>
</tr>
<tr>
<td>16.55</td>
<td>What have genetic studies of osteoporosis taught us and how can we translate this to the clinic</td>
<td>Prof Stuart Ralston, University of Edinburgh, Edinburgh</td>
</tr>
</tbody>
</table>

### SIG: Osteoarthritis

**Chair:** Dr Fraser Birrell, University of Newcastle, Newcastle

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/St (University, Location)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Osteoarthritis trials bank update</td>
<td>Prof Michael Doherty, University of Nottingham, Nottingham</td>
</tr>
<tr>
<td></td>
<td>INBANK</td>
<td>Prof George Peat, Keele University, Keele</td>
</tr>
<tr>
<td>16.30</td>
<td>Small group discussion</td>
<td>Dr Fraser Birrell, University of Newcastle, Newcastle</td>
</tr>
<tr>
<td>17.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
16.00 – 17.30 SIG: RA Outcomes
Chair: Dr Adam Young, West Hertfordshire Hospitals NHS Trust, St Albans

**Aim:**
To explain and explore several recent initiatives in the presentation and management of early adult inflammatory arthritis (AIA)

**Outcome 1:**
Understanding the need for and likely format and impact of the INBANK hub for AIA

**Outcome 2:**
How the INBANK AIA hub relates to other important recent and related initiatives like BSR audit and the MRC/ABPI projects, and the NICE assessment programme for biological therapies

**Outcome 3:**
The impact of these initiatives on both academic and non-academic rheumatology departments in the UK

16.00
**Introduction to Early Adult Inflammatory Arthritis (AIA). How can you be involved in several new and exciting national Initiatives**
*Dr Adam Young, St Albans City Hospital, St Albans*

16.10
**The ARUK INBANK AIA Hub project: clinical and academic involvement**
*Prof Ann Morgan, St James’ University Hospital, Leeds*

16.30
**HQIP and BSR audit of RA**
*Dr Ian Rowe, Worcestershire Acute Hospitals NHS Trust, Worcester*

16.50
**The MRC Patient Stratification Initiative and Early AIA**
*Prof Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, London*

17.10
**BSR NICE negotiations and biologic agents**
*Dr Chris Deighton, Derby Hospitals NHS Trust, Derby*

17.20
**Open discussion**

---

16.00 – 17.30 SIG: Vasculitis
Chair: Prof Raashid Luqmani, University of Oxford, Oxford

**Aim:**
To improve awareness of different forms of vasculitis, to update attendees on the current studies in progress to increase our understanding of the vasculitides, including diagnostic strategies, treatment and outcome

**Outcome 1:**
To learn more about IgG4 related disease and how it is linked to vasculitis

**Outcome 2:**
To understand what progress has been made in ongoing and new initiatives in clinical studies and trials in vasculitis

**Outcome 3:**
To know what role attendees could play in current and future studies in vasculitis

16.00
**IgG4 related disease**
*Dr Emma Culver, University of Oxford, Oxford*

16.20
**Developing patient-related outcome measures in vasculitis**
*Dr Joanna Robson, University of Oxford, Oxford*

16.40
**To be announced**
*Dr Richard Watts, University of East Anglia, Norwich*

17.05
**Update on current vasculitis studies in diagnosis and assessment of vasculitis in adults and children. Brief update on European and other international studies in vasculitis**
*Prof Raashid Luqmani, University of Oxford, Oxford*
**SIG: Interstitial lung disease**

*Chair: Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead*

**Aim:** To share with members the results of the first multi-centre UK study of the outcome of ILD in RA in the biologics era, and develop mechanisms for extending this work into prospective studies. To explore the links between both acute and chronic lung infection in patients with RA and understand the implications for clinical practice.

**Outcome 1:** To inform everyone of the changing natural history of RA-ILD as seen across the UK through a cohort of over 250 patients drawn from six different centres and to discuss the reasons for the improvement - and the implications for therapy.

**Outcome 2:** To present results of a major collaborative project exploring the pivotal role of anti-CCP antibody in the development of bronchiectasis in patients both with and without RA - and the implications for future treatment paradigms.

**Outcome 3:** To review the data on the contribution of acute pulmonary infection to the morbidity and mortality associated with RA, and discuss its implications for our patients. Death from pulmonary disease in its many forms has now overtaken vascular disease as the number one cause of mortality in RA in the UK.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Welcome and introduction</td>
<td></td>
</tr>
<tr>
<td>16.05</td>
<td>ERAS / ERAN experience of lung disease in rheumatoid arthritis</td>
<td>Dr Adam Young, St Albans City Hospital, St Albans</td>
</tr>
<tr>
<td>16.25</td>
<td>UK database on RA-ILD: 25 years of data on predictors, imaging, therapeutics and survival</td>
<td>Dr Clive Kelly, Queen Elizabeth Hospital, Gateshead</td>
</tr>
<tr>
<td>16.45</td>
<td>Interstitial lung disease in rheumatoid arthritis: a chest physician’s perspective</td>
<td>Dr Felix Woodhead, University Hospital, Coventry</td>
</tr>
<tr>
<td>17.05</td>
<td>Bronchiectasis in rheumatoid arthritis: clinical and immunological features</td>
<td>Dr Elizabeth Perry, Arthritis Research UK research fellow, Royal Cornwall Hospital, Truro</td>
</tr>
<tr>
<td>17.25</td>
<td>Group discussion on further priorities for research and education</td>
<td></td>
</tr>
</tbody>
</table>

**17.30**

End of meeting
Registration package
All registration rates include the following:
- Entry to the scientific session of your choice on the days for which you have registered.
- Entry to the exhibition
- Delegate bag (subject to availability for those registering on site)
- Lunch and refreshments
- Welcome reception (for those registered for Tuesday and/or Wednesday)

Register online now
Registering for Rheumatology 2013 is easy. Simply visit www.rheumatology.org.uk/registration to book your place at the UK’s leading rheumatology event. If you wish to pay for your conference place via invoice, you can request an invoice online. Please note that all registration fees must be paid in full before 23 April 2013. Online registration closes at 17.00 on Friday 19 April 2013.

On-site registration
If there are places available, you can register for the conference on-site. Please note that registration rates will be higher on-site as they will include an additional admin fee. We are not able to issue invoices on-site. Save money, avoid the queues at registration and guarantee your place by booking online now at www.rheumatology.org.uk/conference

Cancellations and amendments
Cancellations received in writing by the BSR events team up until 17.00 on Friday 22 March 2013, will be refunded in full minus a £20 cancellation. We regret that we cannot offer refunds for cancellations received after this date, although substitutions may be made, this will incur a £20 administration fee.

Please contact Lindsay McClenaghan: lmcclenaghan@rheumatology.org.uk for any registration queries.
“Nobody working in rheumatology can afford to miss this excellent meeting”
Exhibition

**Rheumatology 2013** is the UK’s leading exhibition for rheumatology professionals where there is something for everyone: network with your colleagues, share ideas, meet with industry partners and get introduced to our free Innovation Theatre Sessions.

The exhibition will take place in **Hall 3 at the ICC** where you can engage with your industry colleagues and learn about their latest products and services. You are invited to visit the exhibition at the following times:

- **Tuesday 23 April** | 08.30 - 17.30
- **Wednesday 24 April** | 08.30 - 17.45
- **Thursday 25 April** | 08.45 - 15.00

**Industry supported symposia**

**Rheumatology 2013** will once again host the popular industry supported symposia. These educational sessions, scheduled during the conference, are a unique platform to listen to exciting new topics and network.

Sessions will be hosted within the ICC, with a maximum of two symposia running concurrently on the following dates:

- **Roche**  
  Tuesday 23 April | 17.30 - 19.15
- **Actelion**  
  Wednesday 24 April | 07.30 - 08.30
- **Pfizer**  
  Wednesday 24 April | 07.30 - 08.30
- **Abbott**  
  Wednesday 24 April | 17.30 - 19.15
- **Bristol Myers Squibb**  
  Thursday 25 April | 07.30 - 08.30

**Exhibitors currently confirmed:**

- 4S Dawn Clinical Software
- A. Algeo Ltd
- A. Menarini Pharma UK S.R.L
- Abbott
- Arthritis Research UK
- BioMarin
- Bristol-Myers Squibb
- Celgene Ltd
- Central Homecare
- GlaxoSmithKline
- Hitachi Medical systems UK LTD
- IL UK Ltd
- Internis Pharma
- Medac GmbH
- Miltenyi Biotec Ltd
- MSD
- Optasia Medical
- Pfizer
- Roche Products Ltd
- Savient Pharma Ireland
- SOBI
- UCB
- Wisepress Ltd

For a full list of exhibitors please visit [www.rheumatology.org.uk/engage](http://www.rheumatology.org.uk/engage)
**NEW Innovation theatre sessions**

Rheumatology 2013 is excited to bring to you the new innovation theatre sessions which will add great value to the conference. The Innovation Theatre will be based within the exhibition hall, where 30 minute sessions will take place daily and be hosted by our exhibitors. Sessions will be varied and will include demonstrations.

**Sessions will be running on the following dates:**
- Tuesday 23 April 10.30 and 11.00
- Tuesday 23 April 13.00 and 13.30
- Wednesday 24 April 10.30 and 11.00
- Thursday 25 April 10.30 and 11.00
- Thursday 25 April 13.00 and 13.30

**Innovation theatre sessions confirmed:**

<table>
<thead>
<tr>
<th>Company</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roche</td>
<td>Tuesday 23 April</td>
<td>11.00 - 11.30</td>
</tr>
<tr>
<td>Abbott</td>
<td>Tuesday 23 April</td>
<td>13.00 - 13.30</td>
</tr>
<tr>
<td>Savient</td>
<td>Tuesday 23 April</td>
<td>13.30 - 14.00</td>
</tr>
<tr>
<td>Roche</td>
<td>Wednesday 24 April</td>
<td>10.30 - 11.00</td>
</tr>
<tr>
<td>Medac</td>
<td>Wednesday 24 April</td>
<td>11.00 - 11.30</td>
</tr>
<tr>
<td>Celegene</td>
<td>Thursday 25 April</td>
<td>10.30 - 11.00</td>
</tr>
<tr>
<td>Abbott</td>
<td>Thursday 25 April</td>
<td>13.00 - 13.30</td>
</tr>
</tbody>
</table>

Please refer to the programme for further details on the Innovation theatre sessions.
Alongside the conference in 2013, BSR will be hosting two evening events, providing entertainment and further networking opportunities to our delegates.

Presidents’ Reception | Tuesday 23 April 2013
The Presidents of BSR and BHPR, Professor Chris Deighton and Mr Robert Field would like to invite all attendees to join them for an evening of drinks, music and socialising with colleagues. This event is free to all delegates and includes drinks and canapés; a wonderful way to spend your evening in Birmingham and wind down after the first day at Rheumatology 2013.

Conference Dinner | Wednesday 24 April 2013
With a lively and diverse culture, Birmingham has a never ending offering of delicious restaurants to try, none better than the popular Shimla Pinks. BSR and BHPR invites guests to carry on networking into the night at the award winning restaurant, enjoying a gourmet Indian feast, socialising and fabulous entertainment along the way, this promises to be an exciting evening.

For further information please visit www.rheumatology.org.uk/2013socialevents

Places are limited so be sure to book early
Tickets are only £40 (Inc VAT)

Facebook group: The British Society for Rheumatology
Linkedin profile name: BSR Comms
Twitter username: @Rheumatologyuk

BSR, Bride House, 18-20 Bride Lane, London EC4Y 8EE
Tel: +44 (0) 20 7842 0900 Fax: +44 (0) 20 7842 0901
Website: www.rheumatology.org.uk

A Charity registered in England and Wales
A Company limited by guarantee
VAT No: 404 5637 66
Company Reg. No: 3470316
Charity No: 1067124